



(86) Date de dépôt PCT/PCT Filing Date: 2003/12/05
(87) Date publication PCT/PCT Publication Date: 2004/06/24
(85) Entrée phase nationale/National Entry: 2005/06/06
(86) N° demande PCT/PCT Application No.: GB 2003/005323
(87) N° publication PCT/PCT Publication No.: 2004/052922
(30) Priorité/Priority: 2002/12/06 (60/431,620) US

(51) Cl.Int.⁷/Int.Cl.⁷ C07K 7/06, A61K 39/395, A61K 38/08,
A61K 39/00, C12N 7/00, C12N 15/11, C07K 14/47,
G01N 33/68, G06F 19/00
(71) Demandeur/Applicant:
SINGAPORE GENERAL HOSPITAL PTE LTD., SG
(72) Inventeur/Inventor:
XIAO, ZHI-CHENG, SG
(74) Agent: BERESKIN & PARR

(54) Titre : LESIONS DU SYSTEME NERVEUX CENTRAL

(54) Title: PEPTIDES, ANTIBODIES THERETO, AND THEIR USE IN THE TREATMENT OF CENTRAL NERVOUS
SYSTEM DAMAGE

(57) **Abrégé/Abstract:**

The application provides peptides that interact with the inhibitory domains of the myelin proteins Nogo, TNF and MAG. These may be used in the treatment for CNS damage, and for the development of further treatments. Also provided are methods and materials for immunizing subjects against the inhibitory domains of the myelin proteins, for the treatment for CNS damage.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/052922 A3

(51) International Patent Classification⁷: **C07K 7/06**,
14/47, G01N 33/68, A61K 38/08, C12N 7/00, G06F
19/00, C12N 15/11, A61K 39/00, 39/395

(21) International Application Number:
PCT/GB2003/005323

(22) International Filing Date: 5 December 2003 (05.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/431,620 6 December 2002 (06.12.2002) US

(71) Applicant (for all designated States except US): **SINGAPORE GENERAL HOSPITAL PTE LTD.** [SG/SG]; 11 Third Hospital Avenue, #07-00, SNEC Building, 168751 Singapore (SG).

(71) Applicant (for MN only): **DENISON, Christopher, M** [GB/GB]; C/o. Mewburn Ellis, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **XIAO, Zhi-Cheng** [CA/SG]; 173 Chin Swee Road, #32-02, 169878 Singapore (SG).

(74) Agents: **DENISON, Christopher, M.** et al.; Mewburn Ellis, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:


— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
28 October 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PEPTIDES, ANTIBODIES THERETO, AND THEIR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE

(57) Abstract: The application provides peptides that interact with the inhibitory domains of the myelin proteins Nogo, TNF and MAG. These may be used in the treatment for CNS damage, and for the development of further treatments. Also provided are methods and materials for immunizing subjects against the inhibitory domains of the myelin proteins, for the treatment for CNS damage.



WO 2004/052922 A3

Central Nervous System Damage

The invention relates to materials and methods useful in the treatment of, or in the development of treatments for, CNS
5 damage, e.g. spinal cord injury or stroke.

Background

Most tissues in the body, such as skin, liver and peripheral
10 nerve, have a remarkable ability to repair themselves after injury. By contrast, the central nervous system (CNS) - including the brain and the spinal cord - has little innate capacity for repair. When axonal connections are damaged in
15 the adult brain or spinal cord, they show an extremely limited ability to regenerate, even though axons can grow and regenerate efficiently in the embryonic CNS and in the adult peripheral nervous system. Factors that account for the inability of CNS axons to regenerate can be grouped in
20 two categories: intrinsic properties of CNS neurons that may make them incapable of regeneration; and extrinsic factors in the CNS environment that are inhibitory to axonal elongation.

The idea that factors in the CNS environment can prevent
25 regeneration dates back to the early 20th century. Ramon y Cajal observed that the inability of adult CNS neurons to extend axonal processes could be overcome by giving them the permissive environment of a peripheral nerve. Then, about 20 years ago, David and Aguayo showed that retinal neurons
30 could form long projections in peripheral nerve grafts. Later, Schwab discovered that dorsal root ganglion neurons in culture extend their axons across Schwann cells but avoid oligodendrocytes and the fatty myelin sheath (Schwab et al 1993).

These results show that failure to regenerate is not purely an intrinsic deficit of CNS neurons, and inhibitory factors in the CNS environment also play an important role. These
5 inhibitory factors are mainly located in the glial scar that forms at the region of injury and by the myelin that ensheaths axons in the white matter tracks.

Following CNS injury, the central area of necrosis is
10 infiltrated by glia and other non-neuronal cells, and a fibrous scar forms. Axons do not extend through the scar and their growth appears to be inhibited by it. Molecular components that may contribute to this inhibitory activity include the extracellular matrix glycoprotein tenascin-R
15 (TN-R) and the myelin-associated neurite outgrowth inhibitors myelin-associated glycoprotein (MAG) and Nogo.

TN-R

20 TN-R has been implicated in a variety of cell-matrix interactions involved in the molecular control of axon guidance and neural cell migration during development and regeneration of CNS (reviewed by Erickson, 1993; Chiquet-Ehrismann et al., 1994; Pesheva et al., 2000; 2001). TN-R
25 is the smallest member of the tenascin family and is composed of four structural motifs: a cysteine-rich segment at the N-terminus is followed by 4.5 EGF-like repeats. This region is followed by 9 consecutive fibronectin type III-like domains and at the C-terminus TN-R is related to the
30 beta- and- gamma-chains of fibrinogen.

TN-R is expressed predominantly by oligodendrocytes during the onset and early phases of myelin formation, and remains expressed by some oligodendrocytes in the adult. TN-R is

also expressed in some neurons and interneurons in the spinal cord, retina, cerebellum, and hippocampus (Fuss et al., 1991; 1993). TN-R co-localizes with other glial-derived molecules (i.e. myelin-associated glycoprotein and a phosphacan-related molecule) at high density in the nodes of Ranvier of CNS myelinated axons (Xiao et al., 1997; Yang et al., 1999).

TN-R can inhibit or promote neurite outgrowth, depending on the neuronal cell type and the environment in which it is presented. When TN-R was offered, acting as a sharp substrate boundary, dorsal root ganglion (DRG), cerebellum and retinal ganglion neuron growth cones avoided growing on these molecules, but were not induced to collapse. On the other hand, when TN-R was offered in a mixture with laminin (which strongly promotes growth of embryonic and adult axons) as a uniform substrate, DRG growth cones displayed a collapsed morphology and were able to advance at a faster rate than on laminin alone.

20

Using several monoclonal antibodies binding to distinct epitopes on the tenascin molecule, epidermal growth factor-like (EGF-L) repeats and fibronectin type III homologous repeats 4-5 were identified to be responsible for growth cone repulsion.

25

In vitro, outgrowth of embryonic and adult retinal ganglion cell axons from mouse retinal explants is significantly reduced on homogeneous substrates of tenascin-R or a bacterially expressed tenascin-R fragment comprising the EGF-L domain. When both molecules are presented, acting as a sharp substrate boundary, regrowing adult axons do not cross into the territory containing tenascin-R or EGF-L. All in vitro experiments were done in the presence of

30

laminin, suggesting that tenascin-R and EGF-L actively inhibit axonal growth. Neurites and growth cones were repelled from areas coated with fragments containing the EGF-L (the amino-terminal cysteine-rich domain plus the EGF-like repeats), FN (fibronectin) 1-2, FN3-5 and FG (fibrinogen) domains of TN-R, and EGF-L prevents neurite outgrowth of hippocampal neurons.

TN-R also induces axonal defasciculation in vitro through the EGF-L domain (Taylor et al., 1993; Xiao et al., 1996, 1997, 1998; Becker et al, 1999; Becker et al, 2000).

After 3-acetylpyridine-induced lesion of the olivocerebellar system of the adult rat, the density of cells containing TN-R transcripts increased significantly in the inferior olivary nucleus and in the white matter of the cerebellar cortex. Immunohistochemical investigations confirmed these observations at the protein level.

After a spinal cord mechanical lesion of rat, TN-R mRNA was also upregulated (Wintergerst et al, 1997; Deckner et al, 2000).

These findings suggested that the continued overexpression of TN-R in the injured CNS may contribute to the failure of adult axonal regeneration in vivo.

Tenascin-R is a member of the tenascin family, which play important roles in cell interactions in the developing nervous system, such as neuronal migration, neuritogenesis, and neuronal regeneration. Tenascin-R is expressed predominantly by oligodendrocytes during the onset and early phases of myelin formation, and remain expressed by some oligodendrocytes in the adult (Pesheva et. al., 1989; Fuss

et al., 1991,1993; Wintergerst et. al., 1993; Ajemian A. et. al., 1994). TN-R is a multi-functional molecule (Lochter and Schachner, 1993; Pesheva et. al., 1993; Taylor et. al., 1993; Xiao et. al., 1996, 1997,1998), and it has indicated
5 that it is an inhibitory component of myelin extraction. Xiao have found that, the EGF-L domain of TN-R can inhibit the neurite outgrowth.

MAG

10

MAG is a transmembrane protein of the immunoglobulin superfamily expressed by myelinating glial cells of the central and peripheral nervous systems, where MAG represents 1 and 0.1% of the total myelin proteins, respectively (Heape
15 at al, 1999). MAG is a potent inhibitor of axonal regeneration and also, depending on the age and type of neuron, can promote axonal growth. MAG inhibits neurite outgrowth of retinal, superior cervical ganglion, spinal, and hippocampal and dorsal root ganglion (DRG) neurons of
20 all postnatal ages, but can enhance neurite outgrowth of embryonic spinal cord neurons and newborn DRG neurons (DeBellard at al, 1996; Turnley et al, 1998; Shen et al, 1998; Yang et al, 1999).

25 MAG can also induce growth cone collapse. 60% of axonal growth cones of postnatal day 1 hippocampal neurons collapsed when they encountered coated recombinant MAG (rMAG). Such collapse was not observed with denatured rMAG (Li et al, 1996). Soluble dMAG (a proteolytic fragment of
30 the extracellular domain of MAG, which is released in abundance from myelin and found in vivo) and chimeric MAG-Fc can potently inhibit neurite outgrowth from P6 DRG neurons. This inhibition was blocked when a MAG monoclonal antibody was included.

These results indicate that soluble dMAG detected in vivo could contribute to the lack of regeneration in the mammalian CNS after injury (Tang et al, 1997; 2001).

5

MAG has two recognition sites for neurons, the sialic acid binding site at R118 and a distinct inhibition site which is absent from the first three Ig domains (Tang et al, 1997).

10 MAG is a well characterized member of the immunoglobulin gene superfamily, and it exerts a robust inhibitory effect on neurite outgrowth from young cerebellar neurons and adult dorsal ganglion (DRG) neurons (Mukhopadhyay et al., 1994). MAG is a membrane protein with 626 amino acids. It has been
15 reported that soluble MAG, which consists of the extracellular domain, has an inhibitory effect on neurite outgrowth (Mckerracher et. al., 1994). The extracellular domain of MAG consists of five Ig-like domains, and it is demonstrated that the first two Ig-like domains are
20 important for the interaction between MAG and neuronal membrane, while the other three Ig-like domains might be involved in the inhibitory effects (Collins et al., 1997).

Nogo

25

Nogo is a high molecular weight integral membrane protein that localizes to CNS myelin, but not PNS myelin. Nogo has three isoforms, named Nogo-A, -B and -C, which are generated by alternative splicing. NI-250 and NI-35 were first
30 identified and named as the 2 isoforms of Nogo; it has now been established that NI-250 is Nogo-A and NI-35 is Nogo-B. Nogo is expressed by oligodendrocytes in white matter of the CNS and is found in the inner and outer leaflets of myelin and in the endoplasmic reticulum.

In vitro characterization of Nogo has demonstrated its function as a potent inhibitor of axon elongation. In vivo neutralization of Nogo activity results in enhanced axonal
5 regeneration and functional recovery following CNS injury as well as increased plasticity in uninjured CNS fibers. The monoclonal antibody mAb IN-1 was shown to promote long-distance regeneration and functional recovery in vivo when applied to spinal cord-injured adult rat (Chen et al, 2000;
10 GrandPre et al; Merkler et al).

These findings suggest that Nogo may be a major contributor to the nonpermissive nature of the CNS environment. Two distinct inhibitory domains of Nogo have been identified: an
15 intracellular amino-terminal domain (NogoN) of Nogo A and a short 66 residue region (Nogo-66) located between two hydrophobic domains of the three isoforms, Nogo-A, Nogo-B and Nogo-C (Chen et al, 2000; GrandPre et al, 2000; Fournier et al , 2001; Filbin, 2003). These domains are illustrated
20 in Science, Vol 297 (5584), 16 Aug 2002, p. 1132-1134.

Nogo-A is expressed by oligodendrocytes but not by Schwann cells. It can inhibit axonal extension and collapses dorsal root ganglion growth cones (GrandPre et. al., 2000). The
25 neurite outgrowth inhibitory activity of Nogo can be neutralized by monoclonal antibody IN-1, which allows axonal regeneration and functional recovery after spinal cord injury (Chen et. al., 2000). Nogo is a membrane protein with 1163 amino acids. The C-terminal tail contains two
30 hydrophobic transmembrane domains separated by a 66-residue hydrophilic extracellular domain. This 66-residue extracellular domain can inhibit axon outgrowth (Fournier et. al., 2001).

Huang et al. (1999) discloses a therapeutic vaccine approach to stimulate axonal regeneration in the adult spinal cord.

5 It is an object of the invention to provide materials and methods useful in the treatment of, or in the development of treatments for, CNS damage, e.g. spinal cord injury, by overcoming the inhibitory effects of myelin on axonal regeneration.

10 **Summary of Invention**

In a first general aspect, the inventor proposes using molecules which interact with the inhibitory domains of major myelin proteins as an adjunct treatment for CNS
15 damage, and for the development of further treatments.

In a second general aspect, the inventor proposes immunizing subjects with the inhibitory domains of major myelin proteins as an adjunct treatment for CNS damage.

20

It may appear impractical to immunize subjects against myelin antigens, as this approach may induce autoimmune demyelinating disease, leading to unacceptable side effects. Also, some myelin antibodies promote remyelination
25 (Rodriguez et al., 1987), which is not of benefit during axonal regeneration. The inventor's approach is, however, to base the vaccine on the specific inhibitory portions of major myelin proteins, instead of whole myelin proteins. Antibodies raised against the inhibitory portions will block
30 the inhibitory effect of myelin on axonal regeneration.

First aspect

Accordingly, the invention provides a peptide, the amino acid sequence of which consists of an amino acid sequence selected from the group consisting of:

YLTQPQS (SEQ ID NO. 1);
5 GSLPHSL (SEQ ID NO. 2);
 TQLFPPQ (SEQ ID NO. 3);
 HSIPDNI (SEQ ID NO. 4);
 HHMPHDK (SEQ ID NO. 5);
 YTTPPSP (SEQ ID NO. 6); and
10 QLPLMPR (SEQ ID NO. 7).

These sequences each represent the deduced amino acid sequences of several peptides that have been identified by phage display as being capable of binding to one or more of
15 the neuronal growth inhibitory molecules Nogo (specifically, the Nogo-66 domain), MAG and TN-R (specifically, TNR-EGFL).

SEQ ID NO. 1 represents the sequence of 43 identical peptides capable of binding to Nogo-66, and also the
20 sequence of 19 identical peptides capable of binding to MAG.

SEQ ID NO. 2 represents the sequence of 8 identical peptides capable of binding to Nogo-66.

25 SEQ ID NO. 3 represents the sequence of 18 identical peptides capable of binding to TNR-EGFL.

SEQ ID NO. 4 represents the sequence of 3 identical peptides capable of binding to TNR-EGFL.

30 SEQ ID NO. 5 represents the sequence of 1 peptide capable of binding to TNR-EGFL.

SEQ ID NO. 6 represents the sequence of 1 peptide capable of binding to TNR-EGFL.

5 SEQ ID NO. 7 represents the sequence of 5 identical peptides capable of binding to MAG.

Of these, SEQ ID NO. 1 has been shown by phage binding to block the inhibitory effects of Nogo-66 and MAG on neuronal cell adhesion in an in vitro assay. Similarly, SEQ ID NO. 3
10 has been shown to block the inhibitory effect of TNR-EGFL. A preferred peptide therefore consists of SEQ ID NO. 1; another preferred peptide consists of SEQ ID NO. 3.

The invention further provides a peptide up to 60 amino
15 acids in length comprising an amino acid sequence selected from the group consisting of:

YLTQPQS (SEQ ID NO. 1);
GSLPHSL (SEQ ID NO. 2);
TQLFPPQ (SEQ ID NO. 3);
20 HSIPDNI (SEQ ID NO. 4);
HHMPHDK (SEQ ID NO. 5);
YTTPPSP (SEQ ID NO. 6); and
QLPLMPR (SEQ ID NO. 7),

wherein the peptide is capable of binding to Nogo
25 (preferably Nogo-66), MAG and/or TN-R (preferably TNR-EGFL).

Preferably, the peptide is up to 50 amino acids in length, more preferably up to 40, up to 30, up to 25, up to 20, up to 19, up to 18, up to 17, up to 16, up to 15, up to 14, up
30 to 13, up to 12, up to 11, up to 10, up to 9, or up to 8 amino acids in length.

A preferred peptide comprises SEQ ID NO. 1; another preferred peptide comprises SEQ ID NO. 3.

The invention further provides a peptide up to 60 amino acids in length comprising an amino acid sequence having at least 5 residues identical with corresponding residues in an amino acid sequence selected from the group consisting of:

5 YLTQPQS (SEQ ID NO. 1);
GSLPHSL (SEQ ID NO. 2);
TQLFPPQ (SEQ ID NO. 3);
HSIPDNI (SEQ ID NO. 4);
10 HHMPHDK (SEQ ID NO. 5);
YTTPPSP (SEQ ID NO. 6); and
QLPLMPR (SEQ ID NO. 7),

wherein the peptide is capable of binding to Nogo (preferably Nogo-66), MAG and/or TN-R (preferably TNR-EGFL).

15 Preferred sizes of the peptide are as stated previously. Peptides having at least 5 residues identical with corresponding residues of SEQ ID NO. 1, or at least 5 residues identical with corresponding residues of SEQ ID NO. 3 are preferred.

20 Preferably the minimum number of identical residues is 6.

The invention further provides a composition comprising one or more peptides of the invention, together with one or more pharmaceutically acceptable ingredients.

25 Preferably the composition is formulated for injection in vivo, preferably for direct injection into the CNS.

30 The invention further provides a peptide of the invention for use in a method of treatment. Such use may be in the treatment of CNS damage, especially spinal cord injury and stroke.

The invention also provides the use of a peptide of the invention in the preparation of a medicament for the treatment of CNS damage, especially spinal cord injury and stroke.

The invention also provides a method for treating CNS damage, the method comprising administering a peptide of the invention to a patient at or near a site of CNS damage in the patient. Specifically, the invention provides a method for treating SCI or stroke, the method comprising administering to a patient a peptide having an amino acid sequence that consists of SEQ ID NO. 1 or 3, by direct injection into a site of SCI or stroke damage in the patient.

The invention also provides the use of a peptide of the invention and/or a computer-generated model thereof, in the design of a mimetic capable of binding to one or more of the neuronal growth inhibitory molecules Nogo (preferably Nogo-66), MAG and/or TN-R (preferably TNR-EGFL).

Similarly, the invention provides a method of designing a mimetic of a peptide of the invention, the mimetic being capable of binding to one or more of the neuronal growth inhibitory molecules Nogo (preferably Nogo-66), MAG and/or TN-R (preferably TNR-EGFL), said method comprising:

(i) analysing a peptide of the invention that is capable of binding to one or more of the neuronal growth inhibitory molecules Nogo (preferably Nogo-66), MAG and/or TN-R (preferably TNR-EGFL) to determine the amino acid residues essential and important for the activity to define a pharmacophore; and

(ii) modelling the pharmacophore to design and/or screen candidate mimetics having the biological activity.

Preferably the method and/or use includes a step of assaying
5 binding of a candidate mimetic to Nogo (preferably Nogo-66),
MAG and/or TN-R (preferably TNR-EGFL) in vitro. Having
identified a candidate mimetic that is capable of such in
vitro binding, the candidate mimetic is preferably optimised
for in vivo use. Following such optimisation, the optimised
10 mimetic is preferably formulated together with one or more
pharmaceutically acceptable ingredients.

The invention further provides a bacteriophage which
expresses a fusion protein consisting of a peptide and a
15 bacteriophage coat protein, such that the peptide is
displayed on the surface of the bacteriophage virion,
wherein the peptide is up to 60 amino acids in length and
comprises an amino acid sequence having at least four
residues identical with corresponding residues of an amino
20 acid sequence selected from the group consisting of:

YLTQPQS (SEQ ID NO. 1);
GSLPHSL (SEQ ID NO. 2);
TQLFPPQ (SEQ ID NO. 3);
HSIPDNI (SEQ ID NO. 4);
25 HHMPHDK (SEQ ID NO. 5);
YTTPPSP (SEQ ID NO. 6); and
QLPLMPR (SEQ ID NO. 7).

Preferably the peptide of the invention is up to 50 amino
30 acids in length, more preferably up to 40, up to 30, up to
25, up to 20, or up to 15 amino acids in length. Still more
preferably, the peptide of the invention is 8-12 amino acids
in length, more preferably 6-10. Preferably the minimum
number of identical residues is 5 or 6.

The invention further provides a screening method for peptides capable of binding to Nogo (preferably Nogo-66), MAG and/or TN-R (preferably TNR-EGFL), the method

5 comprising:

providing bacteriophages of the invention, respectively expressing different peptides; and

screening the bacteriophages for the ability to bind to Nogo (preferably Nogo-66), MAG and/or TN-R (preferably TNR-EGFL).

Bacteriophages which are identified as being capable of binding to Nogo (preferably Nogo-66), MAG and/or TN-R (preferably TNR-EGFL), or the peptides they display, may then be screened for the ability to block the inhibitory effects of Nogo (preferably Nogo-66), MAG and/or TN-R (preferably TNR-EGFL) on neuronal cell adhesion in an in vitro assay. Following the identification of a peptide (or phage that displays a peptide) that is capable of blocking the inhibitory effects of Nogo (preferably Nogo-66), MAG and/or TN-R (preferably TNR-EGFL) on neuronal cell adhesion in an in vitro assay, the peptide is preferably formulated with one or more pharmaceutically acceptable ingredients for administration in vivo.

25

The invention further provides a method of searching for factors that are likely to reduce the inhibitory effect of TN-R, MAG and/or Nogo, the method comprising interrogating a sequence database to identify polypeptides, or nucleic acids that encode polypeptides, that comprise an amino acid sequence having at least 5 residues identical with corresponding residues in an amino acid sequence selected from the group consisting of:

YLTQPQS (SEQ ID NO. 1);

GSLPHSL (SEQ ID NO. 2);
TQLFPPQ (SEQ ID NO. 3);
HSIPDNI (SEQ ID NO. 4);
HHMPHDK (SEQ ID NO. 5);
5 YTPPSP (SEQ ID NO. 6); and
QLPLMPR (SEQ ID NO. 7).

The database is preferably a cDNA database. It may be an EST database. Preferably it is a database of sequences
10 expressed in mammalian CNS. Less specific databases may be used, although this may generate more false positive results.

The invention further provides a method of searching for
15 factors that are likely to reduce the inhibitory effect of TN-R, MAG and/or Nogo, the method comprising screening a cDNA library with an oligonucleotide probe which is capable of hybridising under stringent conditions with a nucleic acid sequence that encodes an amino acid sequence having at
20 least 5 residues identical with corresponding residues in an amino acid sequence selected from the group consisting of:

YLTQPQS (SEQ ID NO. 1);
GSLPHSL (SEQ ID NO. 2);
TQLFPPQ (SEQ ID NO. 3);
25 HSIPDNI (SEQ ID NO. 4);
HHMPHDK (SEQ ID NO. 5);
YTPPSP (SEQ ID NO. 6); and
QLPLMPR (SEQ ID NO. 7).

30 The cDNA library is preferably mammalian, more preferably human. The library is preferably derived from CNS tissue.

Each of the two preceding methods preferably further includes a step, following the identification of a candidate

polypeptide, or nucleic acid encoding the candidate polypeptide, of testing the polypeptide for the ability to reduce the inhibitory effect of TN-R, MAG and/or Nogo. Preferred further steps are as indicated above.

5

Second aspect

In this aspect, the invention provides nucleic acid vector comprising nucleic acid encoding one or more polypeptide domains selected from the group consisting of:

- (a) the N-terminal (NogoN) domain of Nogo-A;
- (b) the extracellular loop (Nogo66) of Nogo-B (also present in Nogo-A and Nogo-C);
- (c) the third to fifth immunoglobulin-like repeats of MAG; and
- (d) the EGF-like domain of TN-R.

The TN-R EGF-L domain has been identified in Xiao et al. (1996) as being capable of inhibiting neurite outgrowth in vitro of a neuronal cell line and primary neurons.

The vector will include control sequences necessary for the expression of said nucleic acid in mammalian cells. Preferably the vector is a commercially available vaccine vector, into which said nucleic acid has been inserted. Suitable and preferred commercially available vaccine vectors include the pcDNA 3.1 family of vectors, especially pcDNA 3.1⁺, and pVAX1 (all from Invitrogen, San Diego, California, US).

30

Usually the nucleic acid will be DNA.

Preferably the nucleic acid encodes at least two of the domains, more preferably at least three, more preferably it

encodes all four. The nucleic acid may encode a plurality of copies of any one or more of the domains.

Where the nucleic acid encodes more than one domain, the domains are preferably expressed as a fusion polypeptide. Preferably the domains are separated from one another by flexible linkers (preferably poly-Ala linkers, e.g. Ala₃ linkers) to facilitate correct folding of the domains.

Of the proteins Nogo A, Nogo B, TN-R and/or MAG (and/or preferably Nogo-C), the vector is preferably capable of expressing substantially only the domains indicated. NogoN is a domain of the Nogo A isoform. Nogo 66 is a domain found in all three isoforms, Nogo-A, Nogo-B and Nogo-C. In particular, the vector is preferably incapable of expressing other epitope-containing portions of the proteins. Of the proteins Nogo A, Nogo B, TN-R and/or MAG (and/or preferably Nogo-C), the vector preferably expresses no more than 20%, more preferably no more than 15%, no more than 12%, no more than 10%, no more than 8%, no more than 6%, no more than 5%, no more than 4%, no more than 3%, no more than 2% or no more than 1% of the protein lying outside the domains listed above. This is particularly preferred for vectors containing a domain or domains of only one of the proteins.

25

The amino acid sequences of Nogo A, Nogo B, Nogo C, TN-R and MAG are available from GenBank, for example under the following accession numbers:

30

MAG - X05301 (GI 56611)
TN-R - Z67996 (GI 1261914)
Nogo B - AJ251384 (GI 9408097)
Nogo A - AF320999 (GI 11878297)
Nogo C - CAB99250 (GI 9408100)

The domains preferably have the amino acid sequences shown below, i.e. for domain (c), the 508 residue amino acid sequence of MAG (1-508); for domain (d), the 205 residue amino acid sequence of TNR (125-329); for domain (a), the 185 amino acid sequence of NogoN (1-185); and for domain (b), the 66 amino acid sequence of Nogo66 (823-888).

MAG (1-508)

10 MIFLTTLPLF WIMISASRGG HWGAWMPSSI SAFEGTCVSI PCRFDLPDEL
 RPAVVHGVWY FNSPYPKNYP PVVFKSRTQV VHESFQGRSR LLGDLGLRNC
 TLLLSTLSPE LGGKYYFRGD LGGYNQYTFS EHSVLDIINT PNIVVPPEVV
 AGTEVEVSCM VPDNCPELRP ELSWLGHEGL GEPTVLGRLR EDEGTWVQVS
 15 LLHFVPTREA NGHRLGCQAA FPNTTLQFEG YASLDVKYPP VIVEMNSSVE
 AIEGSHVSLI CGADSNPPPL LTWMRDGMVL REAVAESLYL DLEEVTPAED
 GIYACLAENA YGQDNRTVEL SVMYAPWKPT VNGTVVAVEG ETVSILCSTQ
 SNPDPIILTIF KEKQILATVI YESQLQLELP AVTPEDDGEY WCVAENQYGO
 RATAFNLSVE FAPIILLES HCAAARDTVQC LCVVKSNPEP SVAFELPSRN
 20 VTVNETEREF VYSERSGLLL TSILTLRGQA QAPPRVICTS RNLYGTQSLE
 LPFQGAHR (SEQ ID NO:8)

TNR (125-329)

25 CPCASS AQVLQELLSR IEMLEREVS VLRDQCNANCC QESAATGQLD
 YIPHCSGHGN FSFESCGCIC NEGWF GKNC S EPYCPLGCSS RGVCVDGQCI
 CDSEYSGDDC SELRCPTDCS SRGLCVDGEC VCEEPYTGED CRELRCPGDC
 SGKGRCANGT CLCEEGYVGE DCGQRQCLNA CSGRGQCEEG LCVCEEGYQG
 PDCSAVAPP (SEQ ID NO:9)

30

NogoN (1-185)

MEDLDQSPLV SSSDSPPRPQ PAFKYQFVRE PEDEEEEEEE EEEDEDEDLE
 ELEVLERKPA AGLSAAPVPT APAAGAPLMD FGND FVPPAP RGPLPAAPPV
 35 APERQPSWDP SPVSSTVPAP SPLSAAAVSP SKLPEDDEPP ARPPPPPPAS
 VSPQAEPVWT PPAPAPAAPP STPAAPKRRG SSGSV (SEQ ID NO:10)

Nogo66 (823-888)

40

RIYKGVIQ AIQKSDEGHP FRAYLESEVA ISEELVQKYS NSALGHVNCT
 IKELRRLFLV DDLVDSLK (SEQ ID NO:11)

45 The vector preferably encodes a polypeptide having the amino acid sequence MAG(1-508)-Ala_n-TNR(125-329)-Ala_n-NogoN(1-

185)-Ala_n-Nogo66(823-888) (SEQ ID NO:12), where Ala_n represents an polyalanine linker. n is preferably 3.

The domains are preferably encoded by the following
 5 sequences, i.e. for domain (c), the 508 codon nucleic acid
 sequence of MAG (126-1649); for domain (d), the 205 codon
 nucleic acid sequence of TNR (454-1068); for domain (a), the
 185 codon nucleic acid sequence of NogoN (1-555); and/or for
 domain (b), the 66 codon nucleic acid sequence of Nogo66
 10 (2467-2664):

MAG (126-1649)

```

15      atgat attccttacc accctgcctc tgtttttggat aatgattttca
      gcttctcgag gggggcactg ggggtgcctgg atgccctcgt ccatctcagc
      cttcgagggc acgtgtgtct ccatcccctg ccgttttcgac ttcccggatg
      agctcagacc ggctgtggta catggcgtct ggtattttcaa cagtccctac
      cccaagaact acccgccagt ggtcttcaag tcccgcacac aagtgggtcca
20      cgagagcttc cagggccgta gccgcctgtt gggagacctg ggcctacgaa
      actgcaccct gcttctcagc acgctgagcc ctgagctggg agggaaatac
      tatttccgag gtgacctggg cggctacaac cagtacacct tctcggagca
      cagcgtcctg gacatcatca acacccccaa catcgtgggtg cccccagaag
      tgggtggcagg aacggaagta gaggtcagct gcatgggtgcc ggacaactgc
25      ccagagctgc gccctgagct gagctggctg ggccacgagg ggctagggga
      gccactgtt ctgggtcggc tgcgggagga tgaaggcacc tgggtgcagg
      tgtcactgct acacttcgtg cctactagag aggccaacgg ccaccgtctg
      ggctgtcagg ctgccttccc caacaccacc ttgcagttcg agggttacgc
      cagtctggac gtcaagtacc ccccggtgat tgtggagatg aattcctctg
30      tggaggccat tgagggtcc cacgtcagcc tgctctgtgg ggctgacagc
      aaccgcccac cgctgctgac ttggatgcgg gatgggatgg tgttgaggga
      ggcagttgct gagagcctgt acctggatct ggaggagggtg accccagcag
      aggacggcat ctatgcttgc ctggcagaga atgcctatgg ccaggacaac
      cgcacgggtg agctgagcgt catgtatgca ccttggaagc ccacagtga
35      tgggacgggtg gtggcggtag agggggagac agtctccatc ctgtgttcca
      cacagagcaa cccggaccct attctcacca tcttcaagga gaagcagatc
      ctggccacgg tcatctatga gagtcagctg cagctggaac tccctgcagt
      gacgcccagag gacgatgggg agtactgggtg thtagctgag aaccagtatg
      gccagagagc caccgccttc aacctgtctg tggagtttgc tcccataatc
40      cttctggaat cgcactgtgc agcggccaga gacaccgtgc agtgcctgtg
      tgtggtaaaa tccaaccgga aacctccgt ggcctttgag ctgccttccc
      gcaacgtgac tgtgaacgag acagagaggg agtttgtgta ctcagagcgc
      agcggcctcc tgctcaccag catcctcacg ctccgggggtc aggcccaagc
      cccacccccgc gtcattttgta cctccaggaa cctctacggc acccagagcc
45      tcgagctgcc tttccaggga gcacaccga (SEQ ID NO:13)
  
```

This sequence commences with a start codon; if any other sequence is used at the 5' end of the nucleic acid, a start codon will be required. It is of course a matter of routine to engineer this into any nucleic acid sequence of interest, though it will be noted that Nogo(1-555) also commences with a start codon.

TNR (454-1068)

```

10      tgtccat gtgccagttc agcccagggtg ctgcaggagc tgctgagccg
      gatcgagatg ctggagaggg aggtgtcggg gctgcgagac cagtgcacgc
      ccaactgctg ccaagaaagt gctgccacag gacaactgga ctatatccct
      cactgcagtg gccacggcaa ctttagcttt gagtcctgtg gctgcatctg
      caacgaaggc tggtttggca agaattgctc ggagccctac tgcccgcctg
15      gttgctccag ccgggggggtg tgtgtggatg gccagtgcac ctgtgacagc
      gaatacagcg gggatgactg ttccgaactc cgggtgccaa cagactgcag
      ctcccggggg ctctgcgtgg acgggggagt tgtctgtgaa gagccctaca
      ctggcgagga ctgcagggaa ctgaggtgcc ctggggactg ttccggggaag
      gggagatgtg ccaacgggtac ctgttttatgc gaggagggtc acgttggtga
20      ggactgcggc cagcggcagt gtctgaatgc ctgcagtggg cgaggacaat
      gtgaggaggg gctctgcgtc tgtgaagagg gctaccaggg ccctgactgc
      tcagcagttg cccctcca (SEQ ID NO:14)

```

NogoN (1-555)

```

25      atggaagacc tggaccagtc tcctctggtc tcgtcctcgg acagcccacc
      ccggccgcag cccgcgttca agtaccagtt cgtgaggagg cccgaggacg
      aggaggaaga agaggaggag gaagaggagg acgaggacga agacctggag
      gagctggagg tgctggagag gaagcccgcc gccgggctgt ccgcggcccc
30      agtgcccacc gcccctgccg ccggcgcgcc cctgatggac ttccggaaatg
      acttcgtgcc gccggcgccc cggggacccc tgccggccgc tccccccgtc
      gccccggagc ggcagccgtc ttgggacccc agcccgggtg cgtcgaccgt
      gcccgcgcca tccccgctgt ctgctgccgc agtctcgccc tccaagctcc
      ctgaggacga cgagcctccg gcccggcctc cccctcctcc cccggccagc
35      gtgagccccc aggcagagcc cgtgtggacc ccgccagccc cggctcccg
      cgcgcccccc tccaccccgg ccgcgcccga gcgcaggggc tcctcgggct
      cagtg (SEQ ID NO:15)

```

Nogo66 (2467-2664)

```

40      agga tatacaaggg tgtgatccaa gctatccaga aatcagatga
      aggccaccca ttcagggcac atctggaatc tgaagttgct atatctgagg
      agttgggttca gaagtacagt aattctgctc ttgggtcatgt gaactgcacg
      ataaaggaac tcaggcgcct cttcttagtt gatgatttag ttgattctct
45      gaag (SEQ ID NO:16)

```

It is, however, thought that fragments, derivatives or variants of these specific domains will also give rise to effective vaccines. Accordingly, a polypeptide domain within the meaning of the invention may be a fragment of any one of the four amino acid sequences given above, the fragment preferably consisting of at least 15 contiguous amino acids from said sequence, more preferably at least 17, more preferably at least 20, 25, 30, 40, 50 or 60 amino acids. For MAG, NogoN and TNR, the size of the fragment is more preferably at least 80 amino acids, more preferably 100, 120, 140, 160 or 180 amino acids. For TNR and MAG, the length is more preferably 200 amino acids. For MAG, the length is more preferably 250, 300, 350, 400 or 450 amino acids. The fragment will include one or more epitopes of the specific domain whose sequence is given above, and will retain the ability of the domain to raise an antibody response in vivo. Thus, the fragment will be capable of raising antibodies in vivo that cross-react with the corresponding domain. Linear epitope mapping is a matter of routine for the skilled person.

Similarly, a polypeptide domain within the meaning of the invention may be a variant of any one amino acid sequence (the reference amino acid sequence) given above. In this context, a variant is a polypeptide having a sequence which differs from the reference amino acid sequence, but which includes a portion of at least 15 amino acids that has at least 65% amino acid identity to a corresponding portion of the reference sequence. Preferably the level of identity is at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%. Preferably the portion is at least 17 amino acids in length, more preferred lengths are those given in the preceding paragraph for the lengths of fragments. Again, the variant will generally include one or more epitopes of the specific

domain whose sequence is given above, and will retain the ability of the domain to raise an antibody response in vivo. Thus, the variant will be capable of raising antibodies in vivo that cross-react with the corresponding domain.

5

The invention also provides a composition comprising the vector of the invention, formulated together with one or more pharmaceutically acceptable ingredients for use as a (therapeutic) vaccine. Preferably the composition is formulated for administration by injection.

10

The invention further provides the vector of the invention, for use in a method of treatment. The treatment may be of CNS damage, especially SCI or stroke.

15

The invention also provides the use of the vector of the invention in the manufacture of a medicament for the treatment of CNS damage, especially SCI and stroke.

20

The invention also provides a method for treating CNS damage in a patient, the method comprising administering a vector of the invention to the patient as a therapeutic vaccine.

25

The vectors of the invention will typically be administered by injection, although other vaccine delivery methods are known in the art (such as oral or transdermal delivery and "needle-free" injection) and may be used in accordance with the invention. Injection will typically be intra-muscular. While the blood-brain barrier normally provides an obstacle to the passage of antibodies, CNS damage (especially injury, e.g. external injury) will generally allow passage of antibodies across the blood-brain barrier at the site of damage. It is considered therefore that no special measures are required to allow passage across the blood-brain barrier

30

of antibodies raised in response to vaccination with the vector of the invention.

The invention further provides a polypeptide consisting
5 essentially of one or more polypeptide domains selected from the group consisting of:

- (a) the N-terminal (NogoN) domain of Nogo-A;
- (b) the extracellular loop of Nogo-B (also present in Nogo-A and Nogo-C);
- 10 (c) the third to fifth immunoglobulin-like repeats of MAG; and
- (d) the EGF-like domain of TN-R.

Preferred features of the polypeptide are as defined above
15 for the polypeptide encoded by the vector.

The invention also provides a composition comprising the polypeptide of the invention, formulated together with one or more pharmaceutically acceptable ingredients for use as a
20 (therapeutic) vaccine. Preferably the composition is formulated for administration by injection.

The invention further provides the polypeptide of the invention, for use in a method of treatment. The treatment
25 may be of CNS damage, especially SCI or stroke.

The invention also provides the use of the polypeptide of the invention in the manufacture of a medicament for the treatment of CNS damage, especially SCI or stroke.

30

The invention also provides a method for treating CNS damage in a patient, the method comprising administering a polypeptide of the invention to the patient as a therapeutic vaccine.

Administration is preferably as described for the vector.

The invention further provides analogous methods and uses of
5 antibodies capable of specifically binding to any one
domains (a)-(d), or preferably mixtures of antibodies
together capable of binding two, three or all four of
domains (a)-(d) for the treatment of CNS damage, especially
SCI or stroke. The antibodies will be administered directly
10 to the patient (preferably as for the peptides of the first
aspect, e.g. by direct injection into the CNS, into the site
of damage or into the cerebro-spinal fluid), instead of
administering a nucleic acid or polypeptide vaccine to
generate an antibody response. Antibody fragments capable
15 of specific binding are regarded to be antibodies for this
purpose.

Detailed description

20 Peptides

The term "peptide" is intended to refer to a molecule
consisting of several amino acids, adjacent pairs of amino
acids being linked by peptide bonds. A peptide bond has the
25 structure -CO-NH-. Amino acids may be naturally occurring
or non-naturally occurring. Terminal amino acids may
include terminal modifications. Naturally occurring chiral
amino acids (i.e. amino acids other than non-chiral glycine)
are of the L-isoform. Peptides of the invention, however,
30 may include or consist of amino acids of the D-isoform.
Such D-amino acids may be the D-isoforms of naturally
occurring L-amino acids, or may have no naturally occurring
L-isoform. The inclusion of D-amino acids in the peptides

of the invention may assist in reducing clearance of the peptide in vivo.

Synthesis of peptides

5

Peptides may be generated wholly or partly by chemical synthesis. The peptides of the invention can be readily prepared according to well-established, standard liquid or, preferably, solid-phase peptide synthesis methods, general
10 descriptions of which are broadly available (see, for example, in J.M. Stewart and J.D. Young, Solid Phase Peptide Synthesis, 2nd edition, Pierce Chemical Company, Rockford, Illinois (1984), in M. Bodanzsky and A. Bodanzsky, The Practice of Peptide Synthesis, Springer Verlag, New York
15 (1984); and Applied Biosystems 430A Users Manual, ABI Inc., Foster City, California), or they may be prepared in solution, by the liquid phase method or by any combination of solid-phase, liquid phase and solution chemistry, e.g. by first completing the respective peptide portion and then, if
20 desired and appropriate, after removal of any protecting groups being present, by introduction of the residue X by reaction of the respective carbonic or sulfonic acid or a reactive derivative thereof.

25 Phage Display

Phage display is a recent and promising technique in biomolecular engineering which can survey tens of millions of short peptides for tight binding to an antibody receptor
30 or other binding protein. Phage display was firstly described in 1985 (Smith et al, 1985) and is a selection technique in which a peptide or protein is expressed as a fusion with a coat protein of a bacteriophage, resulting in display of the fused protein on the surface of the virion,

while the DNA encoding the fusion resides within the virion. Phage display creates a physical linkage between a vast library of random peptide sequences and DNA encoding each sequence, allowing rapid identification of peptide ligands
5 for a variety of target molecules by an in vitro selection process called panning (Scott et al, 1990; Arap et al 1998).

Interactions that involve particular protein domains (either protein/protein or protein/non-protein interactions)
10 typically only need 8-12 amino acids, among which 5-8 amino acids play a key role. Phage display libraries displaying peptides of 6-10 amino acid residues have been successfully used in a number of applications, including epitope mapping, mapping protein-protein contacts, identification of peptide
15 mimetics of non-peptide ligands and design of novel vaccine and new drugs (Scott et al, 1990; Cwirla et al, 1990; Devlin et al 1990 Felici et al, 1991; Motti et al, 1994; Hong et al, 1995; Arap et al, 1998; Nilsson et al, 2000).

20 Recent work has shown that a series of peptides isolated using a broad range of enzymes as targets contained similar amino acid sequences for each target and bound one or two sites per target by competition analysis. Of 17 peptides tested, 13 were found to be specific inhibitors of enzyme
25 function. Peptidic surrogate ligands identified using phage display are preferentially targeted to a limited number of sites that inhibit enzyme function (Hyde-DeRuyscher et al 2000).

30 Mimetics

Non-peptide "small molecules" are often preferred to peptides for in vivo pharmaceutical use. Accordingly,

mimetics of the peptides of the invention may be designed for pharmaceutical use.

5 The designing of mimetics to a known pharmaceutically active compound is a known approach to the development of pharmaceuticals based on a "lead" compound. This might be desirable where the active compound is difficult or expensive to synthesise or where it is unsuitable for a particular method of administration, e.g. peptides are
10 unsuitable active agents for oral compositions as they tend to be quickly degraded by proteases in the alimentary canal. Mimetic design, synthesis and testing is generally used to avoid randomly screening large number of molecules for a target property.

15

There are several steps commonly taken in the design of a mimetic from a compound having a given target property. Firstly, the particular parts of the compound that are critical and/or important in determining the target property
20 are determined. In the case of a peptide, this can be done by systematically varying the amino acid residues in the peptide, e.g. by substituting each residue in turn. Alanine scans of peptide are commonly used to refine such peptide motifs. These parts or residues constituting the active
25 region of the compound are known as its "pharmacophore".

Once the pharmacophore has been found, its structure is modelled according to its physical properties, eg stereochemistry, bonding, size and/or charge, using data
30 from a range of sources, eg spectroscopic techniques, X-ray diffraction data and NMR. Computational analysis, similarity mapping (which models the charge and/or volume of a pharmacophore, rather than the bonding between atoms) and other techniques can be used in this modelling process.

In a variant of this approach, the three-dimensional structure of the ligand and its binding partner are modelled. This can be especially useful where the ligand and/or binding partner change conformation on binding, allowing the model to take account of this in the design of the mimetic.

A template molecule is then selected onto which chemical groups which mimic the pharmacophore can be grafted. The template molecule and the chemical groups grafted on to it can conveniently be selected so that the mimetic is easy to synthesise, is likely to be pharmacologically acceptable, and does not degrade *in vivo*, while retaining the biological activity of the lead compound. Alternatively, where the mimetic is peptide based, further stability can be achieved by cyclising the peptide, increasing its rigidity. The mimetic or mimetics found by this approach can then be screened to see whether they have the target property, or to what extent they exhibit it. Further optimisation or modification can then be carried out to arrive at one or more final mimetics for *in vivo* or clinical testing.

Sequence identity

Percent (%) amino acid sequence identity with respect to a reference sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. % identity values may be determined by WU-BLAST-2 (Altschul et al., Methods in

Enzymology, 266:460-480 (1996)). WU-BLAST-2 uses several search parameters, most of which are set to the default values. The adjustable parameters are set with the following values: overlap span = 1, overlap fraction = 0.125, word
5 threshold (T) = 11. A % amino acid sequence identity value is determined by the number of matching identical residues as determined by WU-BLAST-2, divided by the total number of residues of the reference sequence (gaps introduced by WU-BLAST-2 into the reference sequence to maximize the
10 alignment score being ignored), multiplied by 100.

Stringent conditions

Stringent conditions may be identified by those that: (1)
15 employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example 50% (v/v) formamide with 0.1% bovine serum
20 albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 760 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x
25 Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

30

The subject

The subject to which the compositions and/or treatments of the invention will be administered will be a mammal,

preferably an experimental animal such as a rodent (e.g. a rabbit, rat or mouse), dog, cat, monkey or ape, or a farm animal such as a cow, horse, sheep, pig or goat. More preferably, the subject is human.

5

Generally, the subject will have CNS damage, usually CNS injury, e.g. a head injury. More preferably, however, the damage is to the spinal cord, e.g. SCI. In experimental animals, the damage may be experimental. The CNS damage may also result from a disease or disorder, e.g. epilepsy, stroke, or a neurodegenerative condition, learning memory-related condition and/or dementia such as Alzheimer's disease or Parkinson's disease.

15 The treatments of the invention will generally be intended for use in conjunction with other therapies, such as surgery and/or rehabilitation.

Formulations

20

It is preferable to present the peptides, mimetics, and vectors of the invention as pharmaceutical formulations (e.g., composition, preparation, medicament) comprising at least one active compound, as defined above, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, including, but not limited to, pharmaceutically acceptable carriers, adjuvants, excipients, buffers, preservatives and stabilisers. The formulation may further comprise other active agents.

30

Thus, the present invention further provides a method of making a pharmaceutical composition as previously defined, the method comprising admixing at least one peptide or vector of the invention together with one or more

pharmaceutically acceptable ingredients well known to those skilled in the art, e.g., carriers, adjuvants, excipients, etc..

5 The term "pharmaceutically acceptable" as used herein pertains to compounds, ingredients, materials, compositions, dosage forms, etc., which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of the subject in question (e.g., human) without
10 excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each carrier, adjuvant, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.

15

Suitable carriers, adjuvants, excipients, etc. can be found in standard pharmaceutical texts, for example Remington's Pharmaceutical Sciences, 20th Edition, 2000, pub. Lippincott, Williams & Wilkins; and Handbook of
20 Pharmaceutical Excipients, 2nd edition, 1994.

Formulations may suitably be injectable formulations, e.g. in the form of aqueous, isotonic, pyrogen-free, sterile solutions, in which the active compound is dissolved. Such
25 liquids may additionally contain other pharmaceutically acceptable ingredients, such as anti-oxidants, buffers, preservatives, stabilisers, bacteriostats, suspending agents, thickening agents, and solutes which render the formulation isotonic with the blood or cerebrospinal fluid.
30 Examples of suitable isotonic carriers for use in such formulations include Sodium Chloride Injection, Ringer's Solution, or Lactated Ringer's Injection. Typically, the concentration of the active compound in the liquid is from about 1 ng/ml to about 10 µg/ml, for example from about

10 ng/ml to about 1 µg/ml. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of
 5 the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.

10 Administration

Administration of the peptides of the invention will generally be by injection, preferably directly into the CNS. Injection may be directly into the site of damage, e.g. into
 15 the site of damage. Alternatively, injection may be into the cerebro-spinal fluid, typically near the site of injury.

Experimental work underlying the invention and embodiments of the invention will now be described, by way of example
 20 only, with reference to the accompanying **Figure 1**, which shows the primers used to isolate the inhibitory domains from the proteins MAG, TN-R and Nogo. Coding sequence (or the complementary strand) is shown in bold. Start (Met) and stop (***) codons are doubly underlined. Restriction sites
 25 are underlined. SEQ ID NOS are as follows:

Primer	SEQ ID NO
MAG1	17
MAG2	18
30 TNR1	19
TNR2	20
NogoN1	21
NogoN2	22
Nogo66-1	23

Nogo66-2 24

Also shown schematically is the resultant construct (SEQ ID NO:25) obtained by digestion and sequential connection of the resultant PCR products. Restriction sites are underlined. Ala-encoding codons are labelled. Coding sequence for each inhibitory domain is represented by the bracketed name of the domain. The stop codon is labelled ***.

10

Aspect 1, Example 1

15 Identification of Nogo domains responsible having inhibitory properties

Repulsion assay

NG108 cells (mouse neuroblastoma - rat glioma hybrid cells, commercially available from the American Tissue Type Culture Collection, Manassas, VA, USA, under accession number ATCC HB-12317) were plated on coated substrates using Nogo1-25, Nogo1-50, Nogo1-66 and GST-Nogo-66 as well as GST as control. Generation and purification of the recombinant domains of Nogo, either alone or as fusion proteins with GST, were performed as previously described (Xiao ZC et al, 1996).

NG108 cells were repelled significantly from Nogo1-50, Nogo1-66, and GST-Nogo-66, but not Nogo1-25 and GST.

Neurite outgrowth assay

NG108 cells were plated on coated substrates using Nogol-25, Nogol-50, Nogol-66, and GST-Nogo-66 as well as GST as control.

- 5 Neurite outgrowth of NG108 cells were inhibited significantly from Nogol-50, Nogol-66, and GST Nogo-66, but not Nogol-25 and GST.

10 **Aspect 1, Example 2**

Screening of novel short peptides against neuronal growth inhibitory molecules TN-R, MAG, and Nogo through phage display technology

15

Purification of TN-R, MAG and Nogo from adult mouse brains was performed by immunoaffinity chromatography as previously described (Pesheva, P et al, 1989). Generation and purification of the recombinant domains of TN-R, MAG, Nogo as fusion proteins with GST were performed as previously described (Xiao ZC et al, 1996). All these proteins were used as phage binding targets for rapid screening, using the Ph.D-7™ phage display peptide library kit (New England Biolabs, Ltd) according to the manufacturer's instructions.

25

Briefly, a library of phages, displaying different peptide sequences, was exposed to a plate coated with the target protein. Unbound phage was washed away and specifically bound phage was eluted by lowering pH. The eluted pool of phage was amplified, and the process was repeated 3-4 times.

30

After 3-4 rounds of affinity selection, several specific phage clones were isolated from 7-mer random peptide phage-displayed libraries and identified by ELISA. The peptide-

encoding sequences of the specific phage clones were determined by automated sequencing. The sequences of peptides which bound specifically to the targeted proteins were obtained.

5

The framework sequence of the phage coat protein, into which a 7-mer peptide-encoding sequence is inserted in each phage, is as follows:

10 TTA TTC GCA ATT CCT TTA GTG GTA CCT TTC TAT TCT CAC TCT (SEQ ID NO:26) ... GGT GGA GGT TCG GCC GAA ACT GTT GAA AGT TGT (SEQ ID NO:27)

15 ... represents the site of insertion of the 7-mer peptide-encoding sequence. A KpnI site is underlined, a EagI site is doubly underlined.

Exemplary 7-mer peptide-encoding sequences are shown below. "n" refers to the number of isolated phages displaying a peptide having the sequence shown (though there was of course some variability in the encoding nucleic acid sequences, owing to the degeneracy of the genetic code). "SIN" is an abbreviation for "SEQ ID NO." and refers to the peptide sequence. The SEQ ID NOS of the nucleic acid sequences are 28-35.

Target	Exemplary nucleic acid	Peptide	SIN
Nogo-66	TAT CTG ACG CAG CCT CAG TCG	YLTQPQS (n=43)	1
Nogo-66	GGT TCT CTG CCT CAT TCG CTG	GSLPHSL (n=8)	2
30 TNR-EGFL	ACG CAG CTG TTT CCT CCT TAG	TQLFPPQ (n=18)	3
TNR-EGFL	CAT TCT ATT CCT GAT AAT ATT	HSIPDNI (n=3)	4
TNR-EGFL	CAT CAT ATG CCT CAT GAT AAG	HHMPHDK (n=1)	5
TNR-EGFL	GGT TCT CTG CCT CAT TCG CTG	GSLPHSL (n=1)	2
TNR-EGFL	TAT ACG ACG CCT CCG AGT CCT	YTTPPSP (n=1)	6

WO 2004/052922

PCT/GB2003/005323

MAG	TAT CTG ACG CAG CCT CAG TCG	YLTQPQS (n=19)	1
MAG	CAG CTT CCG CTT ATG CCT CGT	QLPLMPR (n=5)	7
MAG	ACG CAG CTG TTT CCT CCT CAG	TQLFPPQ (n=7)	3

5

Aspect 1, Example 3

In vitro assay for phages displaying peptides that reduce
the inhibitory effect of Nogo, MAG and TN-R on neuronal
5 adhesion

Tissue culture petri dishes (Becton Dickinson) with a
diameter of 3.5 cm were coated with methanol-solubilized
nitrocellulose according to Lagenaur and Lemmon (1987) and
10 air-dried under a sterile hood. Then the petri dishes were
incubated with PBS containing 5 µg/ml poly-DL-ornithine for
2 hours at 37°C. Subsequently, the dishes were washed three
times with PBS and dried under a sterile hood.

15 Protein spots (1.5 µl of 5 µM GST, 5 µM GST-Nogo66, 100µM
Nogo66, 100 µM Nogo1-50 or 100 µM Nogo1-25) were applied to
the nitrocellulose-coated surfaces of the petri dishes and
incubated for 2 hours at 37°C in a humidified atmosphere.
Subsequently, the spots were washed three times with PBS.

20 The dishes were then flooded with PBS containing 2% heat-
inactivated fatty acid-free BSA (Sigma) and incubated
overnight to block residual non-specific protein binding
sites.

25 Then, the dishes were washed with PBS and NG108 cells were
plated in 2 ml of Dulbecco's modified Eagle's medium
containing 10% fetal bovine serum at a density of 2.5×10^5
cells/ml and incubated at 37°C in a humidified atmosphere.
After 12 hours, the dishes were gently washed three times
30 with PBS and the cells fixed by flooding with PBS containing
2.5% glutaraldehyde. After fixation, cultures were stained
with 0.5% toluidine blue (Sigma) in 2.5% sodium carbonate.
The stained cultures were then washed three times with water
and air-dried.

Cells adhering to the various spots were photographed and counted. All experiments were performed at least three times. Statistical analysis was carried out by Student test.

5 The level of significance was chosen as $p < 0.05$.

GST-Nogo66, Nogo66 and Nogo1-50 all displayed significantly reduced NG108 cell counts compared to GST; Nogo1-25 did not.

10 NG108 cells were plated on poly-DL-ornithine-treated tissue culture petri dish as single-cell suspensions. Specific phages that display the Nogo66-, MAG- and TNR-binding peptides identified above were added to the cell culture. Cells were maintained for 24 hours before fixation and
15 staining with toluidine blue. Cell adhesion was determined as previously described.

Phage displaying the peptide YLTQPQS (SEQ ID NO. 1) was able to block the inhibitory effects of Nogo-66 and MAG on NG108
20 cell binding; phage displaying the peptide TQLFPPQ (SEQ ID NO. 3) was able to block the inhibitory effect of TNR-EGFL on NG108 cell binding.

25 **Aspect 1, Example 4**

In vitro assay for peptides that reduce the inhibitory effect of Nogo, MAG and TN-R on neuronal adhesion

30 All the screened consensus peptides are synthesized using the solid-phase method by means of a Peptide Synthesizer Model 1000. Neurite outgrowth and growth cone repulsion assays are performed as described previously (Xiao ZC et al, 1997). Purified intact TN-R, MAG and Nogo and recombinant

domains of TN-R, MAG and Nogo are be coated as substrate, to allow identification of the inhibitory domains of TN-R, MAG and Nogo. In a further assay, the synthesized peptides are mixed with the relevant protein/domain before coating, to
5 identify peptides that can neutralize the inhibitory effects of TN-R, MAG and/or Nogo in vitro.

Aspect 1, Example 5

10

In vivo test for peptides that can alleviate spinal cord injury

Those consensus short peptides that can neutralize the
15 inhibitory effects of TN-R, MAG and/or Nogo in vitro are used in vivo to determine that they alleviate spinal cord injury (Bregman et al, 1995). These peptides are injected into spinal cord injured adult rat. Regeneration of axons is assayed by immunohistochemistry by comparison with an
20 untreated control. Function improvement is also analyzed.

Aspect 1, Example 6

25 Screening for candidate factors that can abolish the inhibitory effects of TN-R, MAG, and/or Nogo

Degenerate oligonucleotide sequences are determined for the peptides that can neutralize the inhibitory effects of TN-R,
30 MAG and/or Nogo in vitro and/or in vivo (preferably both). EST databases (preferably databases of CNS-derived ESTs) are searched using the degenerate oligonucleotide sequences. CNS cDNA libraries are screened using labelled degenerate oligonucleotide probes. Hits represent candidate factors

that can abolish the inhibitory effects of TN-R, MAG and/or Nogo. These candidate factors are purified as GST-fusion protein, and the neutralizing effects are tested as described previously for the peptides.

5

An alternative way to test the neutralizing effects in vivo is to transplant candidate factor-transfected neurons to the injured spinal cord in an experimental animal and observe the neutralizing results.

10

New factors that can abolish the inhibitory effects of TN-R, MAG and/or Nogo are therefore obtained, and are useful for treating, or in the development of treatments for, CNS damage, especially spinal injury.

15

Aspect 2, Example 1

Vector Construction

20 Nucleic acid encoding the following domains was obtained by PCR: N-terminal and 66-Aa extracellular domain of Nogo-A, third to fifth Ig like domain of MAG and the EGF like domain of human TNR.

PCR primers were designed to include restriction enzyme
25 sites and to encode Ala linkers at the ends of the subcloned sequences (see Fig. 1). Therefore, when the PCR products were double digested by restriction enzymes and then connected sequentially, DNA encoding the Ala linkers was located between each pair of neighbouring domains (again,
30 see Fig. 1). The Ala linkers facilitate proper folding of the domains.

Then, the sequentially connected DNA was double digested by BamH I and XbaI and then inserted into a pcDNA 3.1 vector (Invitrogen) to produce a recombinant vector. The recombinant vector was verified by agarose gel and sequence
5 analysis.

Aspect 2, Example 2

10 Verification of the inhibitory functions of the recombinant vector in vitro

Before the DNA vaccine can be injected into test animals, in vitro testing must be carried out to make sure that the vaccine can be expressed by mammalian cells and can be
15 secreted out of the cell to stimulate the immune system of the host.

To check this, COS-1 cells were transfected with the recombinant vector. After transient expression, the cells
20 and the medium were collected respectively and Western-Blot was performed using antibodies to the inhibitory molecules (Xiao et al, 1996) to verify that the recombinant protein is secreted out the cell and can act as an antigen to stimulate the host immune system when the vector is administered in
25 vivo as a vaccine.

Transfected cells were detected positive for MAG and TNF antibodies compared to non-transfected cells.
Immunoreactivity for Nogo was detected in both transfected
30 and non-transfected cells.

48 hours after transient transfection with the recombinant plasmid, the medium was collected and immunoprecipitated

with anti-NogoN or anti-TNR-EGFL antibody using protein A-
agarose. The precipitates were separated by 10% and 6% SDS-
PAGE and probed for Nogo and TNR, respectively. Each
precipitate revealed immunoreactivity for the corresponding
5 antibody, indicating that the protein is being secreted.

Aspect 2, Example 3

10 Dot-blot of GST fusion proteins with pre-immune sera and anti-sera

Anti-sera were collected from Lewis rats after 2-month
vaccination with recombinant plasmid. A serial
15 concentration of GST-Nogo66, GST-NogoN, GST-TNR/EGFL, GST-
MAG Ig3-5 and GST were dotted as substrates and subsequently
blotted with sera. Anti-sera specially recognized GST
fusion proteins, but not GST. Pre-immune sera recognised
neither the fusion proteins, nor GST.

20

Aspect 2, Example 4

Trial of the recombinant vector as a DNA vaccine

25

To check the regeneration of the injured spinal cord after
immunization with the DNA vaccine, the recombinant DNA
vector is injected into a test animal. The anti-serum of
immunized animals is assayed to verify the immune response
30 after the injection of DNA vaccine.

A semi-transected model for spinal cord injury is used.
After a period of time, a morphological study of the injured

spinal cord neuron/axon, and a behavioral study of the animals is performed.

(1) Immunization and spinal cord lesioning

5

6 week-old female Lewis rats are immunized once weekly with 100µg of recombinant vector from the preceding examples. pcDNA3.1 vector lacking the insertion is used as a control. The vector is injected into the back of the rat. After the rats have produced anti-serum, the spinal cords are lesioned. The rats continue to receive twice monthly immunizations for another 6 weeks.

10

The rats are anesthetized with Somnitol (1mg/20g body weight), and a lower thoracic laminectomy is done (T9). The dorsal half of the spinal cord is then cut with a pair of microscissors to sever the corticospinal tracts. The depth of each lesion, about 1mm, is estimated by a mark placed on the tip of the micro-scissors. After a 6 week survival period post lesion, the rats are anesthetized and a 5% solution of WGA-HRP (wheat germ agglutinin-horseradish peroxidase) is injected onto the sensory-motor cortex as described (Li et al., 1996). 48 hours after injection of WGA-HRP, the animals are sacrificed by intracardiac perfusion, and the longitudinal cryostat section of the spinal cord is reacted for HRP histochemistry as described (Li et al., 1996).

20

25

(2) Verification of the immuno-response of the immunized animals

30

To verify that the antisera of the immunized animals have the function of blocking the inhibitory effect of the inhibitory domains on neurite outgrowth, a neurite growth

assay is used to test the serum of the immunized animals. A 4-well dish is first coated with solubilized nitrocellulose and preincubated with 5µg/ml poly-L-lysine. The GST fusion inhibitory domains or peptides are placed in the well as a 2µl drop and then incubated for 4 hrs at 37°C. These wells are then incubated overnight at 4°C with the serum from either control mice or mice immunized with the DNA vaccine. The serum is removed, and postnatal day 10 rat cerebellar neurons purified by Percoll density gradient centrifugation are plated at a density of 1×10^6 cells per well. The cells are cultured in serum-free chemically defined medium for 24 hrs, fixed with 4% paraformaldehyde, and stained with Coomassie blue. Neurite length is measured using a Universal Image I image analysis system. Data is analyzed using the Student-Newman-Keul's test to determine statistically significant differences (Li et. al., 1996).

(3) Morphological study of the injured spinal cord

To check the regeneration of the transected axon, the rats are perfused with 4% paraformaldehyde, and a 10µm thick longitudinal cryostat section of the spinal cord is picked up on gelatin-coated glass slides. The sections are incubated with a biotinylated goat anti-rat antibody overnight and then with streptavidin-conjugated fluorescein for 1 hr, to detect circulating antibodies.

(4) Functional testing of the animals

The functional recovery of the experimental rat is also carried out. Contact placing response is tested by lightly touching the dorsal aspect of the hind limb without causing joint displacement. The ability of the animals to lift the foot and place it onto the support surface is then assessed

in three to six repetitions. Greater than a 30% response will be scored as positive (Kukel-Bagden et. al., 1993).

(5) Safety testing

5

The safety of this vaccination approach is assessed by administering the vaccine to test animals (unlesioned and lesioned) and looking for adverse events, especially loss of sensory or motor function and behavioral or cognitive
10 impairments.

CNS tissue is examined histologically to look for autoimmune damage, e.g. by immunostaining using monoclonal anti-CNPase (Sigma C5922, lot 71k4889). CNPase is a protein expressed
15 by oligodendrocytes, 2',3'-cyclic nucleotide 3'-phosphodiesterase.

Although the foregoing invention has been described in some
20 detail by way of illustration and example for purposes of clarity and understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope
25 of the appended claims.

All documents cited herein are incorporated by reference in their entirety and for all purposes.

30

References

- Ajemian A, Ness R, David S. Tenascin in the injured rat optic nerve and in non-neuronal cells in vitro: potential role in neural repair. *J Comp Neurol*. 1994 Feb 8; 340(2): 233-42
- Altschul SF, Gish W. Local alignment statistics. *Methods Enzymol* 1996;266:460-80.
- Arap W, Pasqualini R, Ruoslahti. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. *Science* 1998 Jan 16;279(5349):377-80.
- Becker CG, Becker T, Meyer RL, Schachner M. Tenascin-R inhibits the growth of optic fibers in vitro but is rapidly eliminated during nerve regeneration in the salamander *Pleurodeles waltl*. : *J Neurosci* 1999 Jan 15;19(2):813-27.
- Becker T, Anliker B, Becker CG, Taylor J, Schachner M, Meyer RL, Bartsch U. Tenascin-R inhibits regrowth of optic fibers in vitro and persists in the optic nerve of mice after injury. *Glia* 2000 Feb 15;29(4):330-46.
- Bregman BS, Kunkel-Bagden E, Schnell L, Dai HN, Gao D, Schwab ME. Recovery from spinal cord injury mediated by antibodies to neurite growth inhibitors. *Nature* 1995 Nov 30;378(6556):498-501.
- Chen MS, Huber AB, Van der Haar ME, Frank M, Schnell L, Spillmann AA, Christ F, Schwab ME. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. *Nature*. 2000 Jan 27; 403(6768):434-9
- Chiquet-Ehrismann R, Tannheimer M, Koch M, Brunner A, Spring J, Martin D, Baumgartner S, Chiquet M. Tenascin-C expression by fibroblasts is elevated in stressed collagen gels. *J Cell Biol* 1994 Dec;127(6 Pt 2):2093-101.
- Collins BE, Yang JS, Mukhopadhyay G, Filbin MT, Kiso M, Hasegawa A, Schnaar RL. Sialic acid specificity of myelin-associated glycoprotein binding. *J Biol Chem*. 1997 Jan 10; 272(2): 1248-55
- Cwirla SE, Peters EA, Barrett RW, Dower WJ. Peptides on phage: a vast library of peptides for identifying ligands. *Proc Natl Acad Sci U S A* 1990 Aug;87(16):6378-82.
- DeBellard ME, Tang S, Mukhopadhyay G, Shen YJ, Filbin MT. Myelin-associated glycoprotein inhibits axonal regeneration

from a variety of neurons via interaction with a sialoglycoprotein. Mol Cell Neurosci 1996 Feb;7(2):89-101.

Deckner M, Lindholm T, Cullheim S, Risling M. Differential expression of tenascin-C, tenascin-R, tenascin/J1, and tenascin-X in spinal cord scar tissue and in the olfactory system. Exp Neurol 2000 Dec;166(2):350-62.

Devlin JJ, Panganiban LC, Devlin PE. Random peptide libraries: a source of specific protein binding molecules. Science 1990 Jul 27;249(4967):404-6.

Erickson HP. Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. Curr Opin Cell Biol. 1993 Oct;5(5):869-76. Review.

Felici F, Castagnoli L, Musacchio A, Jappelli R, Cesareni G. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J Mol Biol 1991 Nov 20;222(2):301-10.

Filbin, MT. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nature Reviews (Neuroscience). September 2003; Vol. 4: 1-11

Fournier AE, Grandpre T, Strittmatter SM. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature. 2001Jan 18; 409: 341-46

Fuss B, Pott U, Fischer P, Schwab ME, Schachner M. Identification of a cDNA clone specific for the oligodendrocyte-derived repulsive extracellular matrix molecules J1-160/180. J Neurosci Res. 1991 Jul; 29(3): 299-307

Fuss B, Bartsch U, Wintergerst ES, Pesheva P, Schachner M. Characterization of the neural recognition molecule janusin (J1-160/180). Schweiz Arch Neurol Psychiatr. 1993; 144(3): 197-8

GrandPre T, Nakamura F, Vartanian T, Strittmatter SM. Identification of the Nogo inhibitor of axon regeneration as a reticulon protein. Nature. 2000 Jan 27; 403: 439-44

Heape AM, Lehto VP, Kursula P. The expression of recombinant large myelin-associated glycoprotein cytoplasmic domain and the purification of native myelin-associated glycoprotein from rat brain and peripheral nerve. Protein Expr Purif 1999 Apr;15(3):349-61.

Hong SS, Boulanger P. Protein ligands of the human adenovirus type 2 outer capsid identified by biopanning of a phage-

displayed peptide library on separate domains of wild-type and mutant penton capsomers. EMBO J 1995 Oct 2;14(19):4714-27.

Huang DW, Mckerracher L, Braun PE, David S. A therapeutic vaccine approach to stimulate axon regeneration in the adult mammalian spinal cord. Neuron. 1999 Nov; 24(3): 639-47

Hyde-DeRuyscher R, Paige LA, Christensen DJ, Hyde-DeRuyscher N, Lim A, Fredericks ZL, Kranz J, Gallant P, Zhang J, Rocklage SM, Fowlkes DM, Wendler PA, Hamilton PT. Detection of small-molecule enzyme inhibitors with peptides isolated from phage-displayed combinatorial peptide libraries. Chem Biol 2000 Jan;7(1):17-25.

Kukel-Bagden E, Dai HN, Bregman BS. Methods to assess the development and recovery of locomotor function after spinal cord injury in rat. Exp Neurol. 1993; 119: 153-64

Lagenaur C, Lemmon V. An L1-like molecule, the 8D9 antigen, is a potent substrate for neurite extension. Proc Natl Acad Sci USA. 1987 Nov;84(21):7753-7

Li M, Shibata A, Li C, Braun PE, Mckerracher L, Roder J, Kater SB, David S. Myelin-associated glycoprotein inhibits neurite/axon growth and causes growth cone collapse. J Neurosci Res. 1996 Nov 15; 46(4): 404-14

Li GL, Farooque M. Expression of ubiquitin-like immunoreactivity in axons after compression trauma to rat spinal cord. Acta Neuropathol (Berl) 1996;91(2):155-60.

Lochter A, Schachner M. Tenascin and extracellular matrix glycoproteins: from promotion to polarization of neurite growth in vitro. J Neurosci. 1993 Sep; 13(9): 3986-4000

Mckerracher L, David S, Jackson DL, Kottis V, Dunn RJ, Braun PE. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron. 1994 Oct; 13(4):805-11

Merkler D, Metz GA, Raineteau O, Dietz V, Schwab ME, Fouad K. Locomotor recovery in spinal cord-injured rats treated with an antibody neutralizing the myelin-associated neurite growth inhibitor Nogo-A. J Neurosci 2001 May 15;21(10):3665-73.

Motti C, Nuzzo M, Meola A, Galfre G, Felici F, Cortese R, Nicosia A, Monaci P. Recognition by human sera and immunogenicity of HBsAg mimotopes selected from an M13 phage display library. Gene 1994 Sep 2;146(2):191-8.

Mukhopadhyay G, Doherty P, Walsh FS, Crocker PR, Filbin MT. A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. *Neuron*. 1994 Sep; 13(3): 757-67

Nilsson MT, Mossing MC, Widersten M. Functional expression and affinity selection of single-chain cro by phage display: isolation of novel DNA-binding proteins. *Protein Eng* 2000 Jul;13(7):519-26.

Pesheva P, Spiess E, Schachner M. J1-160 and J1-180 are oligodendrocyte-secreted nonpermissive substrates for cell adhesion. *J Cell Biol*. 1989 Oct; 109(4 Pt 1): 1765-78

Pesheva P, Gennarini G, Goridis C, Schachner M. The F3/11 cell adhesion molecule mediates the repulsion of neurons by the extracellular matrix glycoprotein J1-160/180. *Neuron*. 1993 Jan; 10(1): 69-82

Pesheva P, Probstmeier R. The yin and yang of tenascin-R in CNS development and pathology. : *Prog Neurobiol* 2000 Aug;61(5):465-93.

Pesheva P, Gloor S, Probstmeier R. Tenascin-R as a regulator of CNS glial cell function. *Prog Brain Res* 2001;132:103-14.

Rodriguez M, Lennon VA, Benveniste EN, Merrill JE. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. *J Neuropathol Exp Neurol* 1987 Jan;46(1):84-95.

Schwab ME. Experimental aspects of spinal cord regeneration. *Curr Opin Neurol Neurosurg*. 1993 Aug; 6(4): 549-53

Scott JK, Smith GP. Searching for peptide ligands with an epitope library. *Science* 1990 Jul 27;249(4967):386-90.

Shen YJ, DeBellard ME, Salzer JL, Roder J, Filbin MT. Myelin-associated glycoprotein in myelin and expressed by Schwann cells inhibits axonal regeneration and branching. *Mol Cell Neurosci* 1998 Sep;12(1-2):79-91.

Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. *Science* 1985 Jun 14;228(4705):1315-7.

Tang S, Woodhall RW, Shen YJ, deBellard ME, Saffell JL, Doherty P, Walsh FS, Filbin MT. Soluble myelin-associated glycoprotein (MAG) found in vivo inhibits axonal regeneration. *Mol Cell Neurosci* 1997;9(5-6):333-46.

Tang S, Shen YJ, DeBellard ME, Mukhopadhyay G, Salzer JL, Crocker PR, Filbin MT. Myelin-associated glycoprotein

interacts with neurons via a sialic acid binding site at ARG118 and a distinct neurite inhibition site. J Cell Biol 1997 Sep 22;138(6):1355-66.

Tang S, Qiu J, Nikulina E, Filbin MT. Soluble myelin-associated glycoprotein released from damaged white matter inhibits axonal regeneration. Mol Cell Neurosci 2001 Sep;18(3):259-69.

Taylor J, Pesheva P, Schachner M. Influence of janusin and tenascin on growth cone behavior in vitro. J Neurosci Res. 1993 Jul 1; 35(4): 347-62

Turnley AM, Bartlett PF. MAG and MOG enhance neurite outgrowth of embryonic mouse spinal cord neurons. : Neuroreport 1998 Jun 22;9(9):1987-90.

Wintergerst ES, Fuss B, Bartsch U. Localization of janusin mRNA in the central nervous system of the developing and adult mouse. Eur J Neurosci. 1993 Apr 1; 5(4): 299-310

Wintergerst ES, Bartsch U, Batini C, Schachner M. Changes in the expression of the extracellular matrix molecules tenascin-C and tenascin-R after 3-acetylpyridine-induced lesion of the olivocerebellar system of the adult rat. Eur J Neurosci 1997 Mar;9(3):424-34.

Xiao ZC, Taylor J, Montag D, Rougon G, Schachner M. Distinct effects of recombinant tenascin-R domains in neuronal cell functions and identification of the domain interacting with the neuronal recognition molecules F3/11. Eur J Neurosci. 1996; 8: 766-82

Xiao ZC, Hillenbrand R, Schachner M, Thermes S, Rougon G, Gomaz S. Signalling events involved following the interaction of the neuronal adhesion molecule F3 with the EGF-L domain of tenascin-R. J Neurosci Res. 1997; 39: 698-709

Xiao ZC, Revest JM, Laeng P, Rougon G, Schachner M, Montag D. Defasciculation of cerebellar neurons is mediated by tenascin-R and its neuronal receptor, the immunoglobulin superfamily molecule F3/F11. J Neurosci Res. 1998; 52: 390-404.

Yang H, Xiao ZC, Becker B, Hillenbrand R, Rougon G, Schachner M. Role for myelin-associated glycoprotein as a functional tenascin-R receptor. J Neurosci Res 1999 Mar 15;55(6):687-701.

SEQUENCE LISTING

<110> Singapore General Hospital Pte Ltd
Xiao, Zhi-Cheng

<120> Central nervous system damage

<130> CMD/FP6186654

<150> US 60/431,620
<151> 2002-12-06

<160> 35

<170> PatentIn version 3.1

<210> 1
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> From a phage library that displays random 7-mers

<400> 1

Tyr Leu Thr Gln Pro Gln Ser
1 5

<210> 2
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> From a phage library that displays random 7-mers

<400> 2

Gly Ser Leu Pro His Ser Leu
1 5

<210> 3
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> From a phage library that displays random 7-mers

<400> 3

Thr Gln Leu Phe Pro Pro Gln
1 5

<210> 4
<211> 7
<212> PRT
<213> Artificial sequence

<220>

<223> From a phage library that displays random 7-mers

<400> 4

His Ser Ile Pro Asp Asn Ile
 1 5

<210> 5

<211> 7

<212> PRT

<213> Artificial sequence

<220>

<223> From a phage library that displays random 7-mers

<400> 5

His His Met Pro His Asp Lys
 1 5

<210> 6

<211> 7

<212> PRT

<213> Artificial sequence

<220>

<223> From a phage library that displays random 7-mers

<400> 6

Tyr Thr Thr Pro Pro Ser Pro
 1 5

<210> 7

<211> 7

<212> PRT

<213> Artificial sequence

<220>

<223> From a phage library that displays random 7-mers

<400> 7

Gln Leu Pro Leu Met Pro Arg
 1 5

<210> 8

<211> 508

<212> PRT

<213> Rattus norvegicus

<400> 8

Met Ile Phe Leu Thr Thr Leu Pro Leu Phe Trp Ile Met Ile Ser Ala
 1 5 10 15

Ser Arg Gly Gly His Trp Gly Ala Trp Met Pro Ser Ser Ile Ser Ala
20 25 30

Phe Glu Gly Thr Cys Val Ser Ile Pro Cys Arg Phe Asp Phe Pro Asp
35 40 45

Glu Leu Arg Pro Ala Val Val His Gly Val Trp Tyr Phe Asn Ser Pro
50 55 60

Tyr Pro Lys Asn Tyr Pro Pro Val Val Phe Lys Ser Arg Thr Gln Val
65 70 75 80

Val His Glu Ser Phe Gln Gly Arg Ser Arg Leu Leu Gly Asp Leu Gly
85 90 95

Leu Arg Asn Cys Thr Leu Leu Leu Ser Thr Leu Ser Pro Glu Leu Gly
100 105 110

Gly Lys Tyr Tyr Phe Arg Gly Asp Leu Gly Gly Tyr Asn Gln Tyr Thr
115 120 125

Phe Ser Glu His Ser Val Leu Asp Ile Ile Asn Thr Pro Asn Ile Val
130 135 140

Val Pro Pro Glu Val Val Ala Gly Thr Glu Val Glu Val Ser Cys Met
145 150 155 160

Val Pro Asp Asn Cys Pro Glu Leu Arg Pro Glu Leu Ser Trp Leu Gly
165 170 175

His Glu Gly Leu Gly Glu Pro Thr Val Leu Gly Arg Leu Arg Glu Asp
180 185 190

Glu Gly Thr Trp Val Gln Val Ser Leu Leu His Phe Val Pro Thr Arg
195 200 205

Glu Ala Asn Gly His Arg Leu Gly Cys Gln Ala Ala Phe Pro Asn Thr
210 215 220

Thr Leu Gln Phe Glu Gly Tyr Ala Ser Leu Asp Val Lys Tyr Pro Pro
225 230 235 240

Val Ile Val Glu Met Asn Ser Ser Val Glu Ala Ile Glu Gly Ser His
245 250 255

Val Ser Leu Leu Cys Gly Ala Asp Ser Asn Pro Pro Pro Leu Leu Thr

260

265

270

Trp Met Arg Asp Gly Met Val Leu Arg Glu Ala Val Ala Glu Ser Leu
 275 280 285

Tyr Leu Asp Leu Glu Glu Val Thr Pro Ala Glu Asp Gly Ile Tyr Ala
 290 295 300

Cys Leu Ala Glu Asn Ala Tyr Gly Gln Asp Asn Arg Thr Val Glu Leu
 305 310 315 320

Ser Val Met Tyr Ala Pro Trp Lys Pro Thr Val Asn Gly Thr Val Val
 325 330 335

Ala Val Glu Gly Glu Thr Val Ser Ile Leu Cys Ser Thr Gln Ser Asn
 340 345 350

Pro Asp Pro Ile Leu Thr Ile Phe Lys Glu Lys Gln Ile Leu Ala Thr
 355 360 365

Val Ile Tyr Glu Ser Gln Leu Gln Leu Glu Leu Pro Ala Val Thr Pro
 370 375 380

Glu Asp Asp Gly Glu Tyr Trp Cys Val Ala Glu Asn Gln Tyr Gly Gln
 385 390 395 400

Arg Ala Thr Ala Phe Asn Leu Ser Val Glu Phe Ala Pro Ile Ile Leu
 405 410 415

Leu Glu Ser His Cys Ala Ala Ala Arg Asp Thr Val Gln Cys Leu Cys
 420 425 430

Val Val Lys Ser Asn Pro Glu Pro Ser Val Ala Phe Glu Leu Pro Ser
 435 440 445

Arg Asn Val Thr Val Asn Glu Thr Glu Arg Glu Phe Val Tyr Ser Glu
 450 455 460

Arg Ser Gly Leu Leu Leu Thr Ser Ile Leu Thr Leu Arg Gly Gln Ala
 465 470 475 480

Gln Ala Pro Pro Arg Val Ile Cys Thr Ser Arg Asn Leu Tyr Gly Thr
 485 490 495

Gln Ser Leu Glu Leu Pro Phe Gln Gly Ala His Arg
 500 505

<210> 9
 <211> 205
 <212> PRT
 <213> Homo sapiens

<400> 9

Cys Pro Cys Ala Ser Ser Ala Gln Val Leu Gln Glu Leu Leu Ser Arg
 1 5 10 15

Ile Glu Met Leu Glu Arg Glu Val Ser Val Leu Arg Asp Gln Cys Asn
 20 25 30

Ala Asn Cys Cys Gln Glu Ser Ala Ala Thr Gly Gln Leu Asp Tyr Ile
 35 40 45

Pro His Cys Ser Gly His Gly Asn Phe Ser Phe Glu Ser Cys Gly Cys
 50 55 60

Ile Cys Asn Glu Gly Trp Phe Gly Lys Asn Cys Ser Glu Pro Tyr Cys
 65 70 75 80

Pro Leu Gly Cys Ser Ser Arg Gly Val Cys Val Asp Gly Gln Cys Ile
 85 90 95

Cys Asp Ser Glu Tyr Ser Gly Asp Asp Cys Ser Glu Leu Arg Cys Pro
 100 105 110

Thr Asp Cys Ser Ser Arg Gly Leu Cys Val Asp Gly Glu Cys Val Cys
 115 120 125

Glu Glu Pro Tyr Thr Gly Glu Asp Cys Arg Glu Leu Arg Cys Pro Gly
 130 135 140

Asp Cys Ser Gly Lys Gly Arg Cys Ala Asn Gly Thr Cys Leu Cys Glu
 145 150 155 160

Glu Gly Tyr Val Gly Glu Asp Cys Gly Gln Arg Gln Cys Leu Asn Ala
 165 170 175

Cys Ser Gly Arg Gly Gln Cys Glu Glu Gly Leu Cys Val Cys Glu Glu
 180 185 190

Gly Tyr Gln Gly Pro Asp Cys Ser Ala Val Ala Pro Pro
 195 200 205

<210> 10
 <211> 185

<212> PRT
 <213> Homo sapiens

<400> 10

Met Glu Asp Leu Asp Gln Ser Pro Leu Val Ser Ser Ser Asp Ser Pro
 1 5 10 15

Pro Arg Pro Gln Pro Ala Phe Lys Tyr Gln Phe Val Arg Glu Pro Glu
 20 25 30

Asp Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Asp Glu Asp Glu Asp
 35 40 45

Leu Glu Glu Leu Glu Val Leu Glu Arg Lys Pro Ala Ala Gly Leu Ser
 50 55 60

Ala Ala Pro Val Pro Thr Ala Pro Ala Ala Gly Ala Pro Leu Met Asp
 65 70 75 80

Phe Gly Asn Asp Phe Val Pro Pro Ala Pro Arg Gly Pro Leu Pro Ala
 85 90 95

Ala Pro Pro Val Ala Pro Glu Arg Gln Pro Ser Trp Asp Pro Ser Pro
 100 105 110

Val Ser Ser Thr Val Pro Ala Pro Ser Pro Leu Ser Ala Ala Ala Val
 115 120 125

Ser Pro Ser Lys Leu Pro Glu Asp Asp Glu Pro Pro Ala Arg Pro Pro
 130 135 140

Pro Pro Pro Pro Ala Ser Val Ser Pro Gln Ala Glu Pro Val Trp Thr
 145 150 155 160

Pro Pro Ala Pro Ala Pro Ala Ala Pro Pro Ser Thr Pro Ala Ala Pro
 165 170 175

Lys Arg Arg Gly Ser Ser Gly Ser Val
 180 185

<210> 11
 <211> 66
 <212> PRT
 <213> Homo sapiens

<400> 11

Arg Ile Tyr Lys Gly Val Ile Gln Ala Ile Gln Lys Ser Asp Glu Gly
 1 5 10 15

His Pro Phe Arg Ala Tyr Leu Glu Ser Glu Val Ala Ile Ser Glu Glu
20 25 30

Leu Val Gln Lys Tyr Ser Asn Ser Ala Leu Gly His Val Asn Cys Thr
35 40 45

Ile Lys Glu Leu Arg Arg Leu Phe Leu Val Asp Asp Leu Val Asp Ser
50 55 60

Leu Lys
65

<210> 12
<211> 973
<212> PRT
<213> Artificial sequence

<220>
<223> Fusion protein

<220>
<221> VARIANT
<222> (509)..(511)
<223> Polyalanine linker.

<220>
<221> VARIANT
<222> (717)..(719)
<223> Polyalanine linker.

<220>
<221> VARIANT
<222> (905)..(907)
<223> Polyalanine linker.

<400> 12

Met Ile Phe Leu Thr Thr Leu Pro Leu Phe Trp Ile Met Ile Ser Ala
1 5 10 15

Ser Arg Gly Gly His Trp Gly Ala Trp Met Pro Ser Ser Ile Ser Ala
20 25 30

Phe Glu Gly Thr Cys Val Ser Ile Pro Cys Arg Phe Asp Phe Pro Asp
35 40 45

Glu Leu Arg Pro Ala Val Val His Gly Val Trp Tyr Phe Asn Ser Pro
50 55 60

Tyr Pro Lys Asn Tyr Pro Pro Val Val Phe Lys Ser Arg Thr Gln Val
65 70 75 80

Val His Glu Ser Phe Gln Gly Arg Ser Arg Leu Leu Gly Asp Leu Gly
85 90 95

Leu Arg Asn Cys Thr Leu Leu Leu Ser Thr Leu Ser Pro Glu Leu Gly
100 105 110

Gly Lys Tyr Tyr Phe Arg Gly Asp Leu Gly Gly Tyr Asn Gln Tyr Thr
115 120 125

Phe Ser Glu His Ser Val Leu Asp Ile Ile Asn Thr Pro Asn Ile Val
130 135 140

Val Pro Pro Glu Val Val Ala Gly Thr Glu Val Glu Val Ser Cys Met
145 150 155 160

Val Pro Asp Asn Cys Pro Glu Leu Arg Pro Glu Leu Ser Trp Leu Gly
165 170 175

His Glu Gly Leu Gly Glu Pro Thr Val Leu Gly Arg Leu Arg Glu Asp
180 185 190

Glu Gly Thr Trp Val Gln Val Ser Leu Leu His Phe Val Pro Thr Arg
195 200 205

Glu Ala Asn Gly His Arg Leu Gly Cys Gln Ala Ala Phe Pro Asn Thr
210 215 220

Thr Leu Gln Phe Glu Gly Tyr Ala Ser Leu Asp Val Lys Tyr Pro Pro
225 230 235 240

Val Ile Val Glu Met Asn Ser Ser Val Glu Ala Ile Glu Gly Ser His
245 250 255

Val Ser Leu Leu Cys Gly Ala Asp Ser Asn Pro Pro Pro Leu Leu Thr
260 265 270

Trp Met Arg Asp Gly Met Val Leu Arg Glu Ala Val Ala Glu Ser Leu
275 280 285

Tyr Leu Asp Leu Glu Glu Val Thr Pro Ala Glu Asp Gly Ile Tyr Ala
290 295 300

Cys Leu Ala Glu Asn Ala Tyr Gly Gln Asp Asn Arg Thr Val Glu Leu
305 310 315 320

Ser Val Met Tyr Ala Pro Trp Lys Pro Thr Val Asn Gly Thr Val Val
 325 330 335

Ala Val Glu Gly Glu Thr Val Ser Ile Leu Cys Ser Thr Gln Ser Asn
 340 345 350

Pro Asp Pro Ile Leu Thr Ile Phe Lys Glu Lys Gln Ile Leu Ala Thr
 355 360 365

Val Ile Tyr Glu Ser Gln Leu Gln Leu Glu Leu Pro Ala Val Thr Pro
 370 375 380

Glu Asp Asp Gly Glu Tyr Trp Cys Val Ala Glu Asn Gln Tyr Gly Gln
 385 390 395 400

Arg Ala Thr Ala Phe Asn Leu Ser Val Glu Phe Ala Pro Ile Ile Leu
 405 410 415

Leu Glu Ser His Cys Ala Ala Ala Arg Asp Thr Val Gln Cys Leu Cys
 420 425 430

Val Val Lys Ser Asn Pro Glu Pro Ser Val Ala Phe Glu Leu Pro Ser
 435 440 445

Arg Asn Val Thr Val Asn Glu Thr Glu Arg Glu Phe Val Tyr Ser Glu
 450 455 460

Arg Ser Gly Leu Leu Leu Thr Ser Ile Leu Thr Leu Arg Gly Gln Ala
 465 470 475 480

Gln Ala Pro Pro Arg Val Ile Cys Thr Ser Arg Asn Leu Tyr Gly Thr
 485 490 495

Gln Ser Leu Glu Leu Pro Phe Gln Gly Ala His Arg Ala Ala Ala Cys
 500 505 510

Pro Cys Ala Ser Ser Ala Gln Val Leu Gln Glu Leu Leu Ser Arg Ile
 515 520 525

Glu Met Leu Glu Arg Glu Val Ser Val Leu Arg Asp Gln Cys Asn Ala
 530 535 540

Asn Cys Cys Gln Glu Ser Ala Ala Thr Gly Gln Leu Asp Tyr Ile Pro
 545 550 555 560

His Cys Ser Gly His Gly Asn Phe Ser Phe Glu Ser Cys Gly Cys Ile
 565 570 575

Cys Asn Glu Gly Trp Phe Gly Lys Asn Cys Ser Glu Pro Tyr Cys Pro
 580 585 590

Leu Gly Cys Ser Ser Arg Gly Val Cys Val Asp Gly Gln Cys Ile Cys
 595 600 605

Asp Ser Glu Tyr Ser Gly Asp Asp Cys Ser Glu Leu Arg Cys Pro Thr
 610 615 620

Asp Cys Ser Ser Arg Gly Leu Cys Val Asp Gly Glu Cys Val Cys Glu
 625 630 635 640

Glu Pro Tyr Thr Gly Glu Asp Cys Arg Glu Leu Arg Cys Pro Gly Asp
 645 650 655

Cys Ser Gly Lys Gly Arg Cys Ala Asn Gly Thr Cys Leu Cys Glu Glu
 660 665 670

Gly Tyr Val Gly Glu Asp Cys Gly Gln Arg Gln Cys Leu Asn Ala Cys
 675 680 685

Ser Gly Arg Gly Gln Cys Glu Glu Gly Leu Cys Val Cys Glu Glu Gly
 690 695 700

Tyr Gln Gly Pro Asp Cys Ser Ala Val Ala Pro Pro Ala Ala Ala Met
 705 710 715 720

Glu Asp Leu Asp Gln Ser Pro Leu Val Ser Ser Ser Asp Ser Pro Pro
 725 730 735

Arg Pro Gln Pro Ala Phe Lys Tyr Gln Phe Val Arg Glu Pro Glu Asp
 740 745 750

Glu Glu Glu Glu Glu Glu Glu Glu Glu Asp Glu Asp Glu Asp Leu
 755 760 765

Glu Glu Leu Glu Val Leu Glu Arg Lys Pro Ala Ala Gly Leu Ser Ala
 770 775 780

Ala Pro Val Pro Thr Ala Pro Ala Ala Gly Ala Pro Leu Met Asp Phe
 785 790 795 800

Gly Asn Asp Phe Val Pro Pro Ala Pro Arg Gly Pro Leu Pro Ala Ala
 805 810 815

Pro Pro Val Ala Pro Glu Arg Gln Pro Ser Trp Asp Pro Ser Pro Val
820 825 830

Ser Ser Thr Val Pro Ala Pro Ser Pro Leu Ser Ala Ala Ala Val Ser
835 840 845

Pro Ser Lys Leu Pro Glu Asp Asp Glu Pro Pro Ala Arg Pro Pro Pro
850 855 860

Pro Pro Pro Ala Ser Val Ser Pro Gln Ala Glu Pro Val Trp Thr Pro
865 870 875 880

Pro Ala Pro Ala Pro Ala Ala Pro Pro Ser Thr Pro Ala Ala Pro Lys
885 890 895

Arg Arg Gly Ser Ser Gly Ser Val Ala Ala Ala Arg Ile Tyr Lys Gly
900 905 910

Val Ile Gln Ala Ile Gln Lys Ser Asp Glu Gly His Pro Phe Arg Ala
915 920 925

Tyr Leu Glu Ser Glu Val Ala Ile Ser Glu Glu Leu Val Gln Lys Tyr
930 935 940

Ser Asn Ser Ala Leu Gly His Val Asn Cys Thr Ile Lys Glu Leu Arg
945 950 955 960

Arg Leu Phe Leu Val Asp Asp Leu Val Asp Ser Leu Lys
965 970

<210> 13
<211> 1524
<212> DNA
<213> Rattus norvegicus

<400> 13
atgatattcc ttaccaccct gcctctgttt tggataatga tttcagcttc tcgagggggg 60
cactggggtg cctggatgcc ctcgtccatc tcagccttcg agggcacgtg tgtctccatc 120
ccctgccgtt tcgacttccc ggatgagctc agaccggctg tggtagatgg cgtctggtat 180
ttcaacagtc cctaccccaa gaactaccg ccagtgggtc tcaagtcccg cacacaagtg 240
gtccacgaga gcttccaggg ccgtagccgc ctgttgggag acctgggcct acgaaactgc 300
accctgcttc tcagcacgct gagccctgag ctgggaggga aatactatct ccgaggtgac 360
ctgggcggct acaaccagta caccttctcg gagcacagcg tcctggacat catcaacacc 420

cccaacatcg tgggtgcccc agaagtgggtg gcaggaacgg aagtagaggt cagctgcatg 480
 gtgccggaca actgcccaga gctgcgccct gagctgagct ggctgggcca cgaggggcta 540
 ggggagccca ctgttctggg tcggctgcgg gaggatgaag gcacctgggt gcagggtgtca 600
 ctgctacact tcgtgcctac tagagaggcc aacggccacc gtctgggctg tcaggctgcc 660
 ttccccaaca ccaccttgca gttcgagggt tacgccagtc tggacgtcaa gtaccccccg 720
 gtgattgtgg agatgaattc ctctgtggag gccattgagg gctcccacgt cagcctgctc 780
 tgtggggctg acagcaaccc gccaccgctg ctgacttgga tgcgggatgg gatgggtgtt 840
 agggaggcag ttgctgagag cctgtacctg gatctggagg aggtgacccc agcagaggac 900
 ggcacttatg cttgcctggc agagaatgcc tatggccagg acaaccgcac ggtggagctg 960
 agcgtcatgt atgcacctg gaagcccaca gtgaatggga cgggtgggtggc ggtagagggg 1020
 gagacagtct ccactctgtg ttccacacag agcaaccgg accctattct caccatcttc 1080
 aaggagaagc agatcctggc cacggtcac tatgagagtc agctgcagct ggaactccct 1140
 gcagtgacgc ccgaggacga tggggagtac tgggtgtgtag ctgagaacca gtatggccag 1200
 agagccaccg ccttcaacct gtctgtggag tttgctccca taatccttct ggaatcgac 1260
 tgtgcagcgg ccagagacac cgtgcagtgc ctgtgtgtgg taaaatccaa cccggaaccc 1320
 tccgtggcct ttgagctgcc ttcccgaac gtgactgtga acgagacaga gagggagttt 1380
 gtgtactcag agcgcagcgg cctcctgctc accagcatcc tcacgctccg gggtcaggcc 1440
 caagccccac cccgcgtcat ttgtacctcc aggaacctct acggcaccca gagcctcgag 1500
 ctgcctttcc agggagcaca ccga 1524

<210> 14
 <211> 615
 <212> DNA
 <213> Homo sapiens

<400> 14
 tgtccatgtg ccagttcagc ccagggtgctg caggagctgc tgagccggat cgagatgctg 60
 gagagggagg tgtcgggtgct gcgagaccag tgcaacgcca actgctgcca agaaagtgtc 120
 gccacaggac aactggacta tatccctcac tgcagtggcc acggcaactt tagctttgag 180
 tcctgtggct gcatctgcaa cgaaggctgg tttggcaaga attgctcgga gccctactgc 240
 ccgctgggtt gctccagccg ggggggtgtgt gtggatggcc agtgcactctg tgacagcgaa 300
 tacagcgggg atgactgttc cgaactccgg tgcccaacag actgcagctc ccgggggctc 360
 tgcgtggacg gggagtgtgt ctgtgaagag ccctacactg gcgaggactg cagggaactg 420
 aggtgccctg gggactgttc ggggaagggg agatgtgcca acggtaacctg tttatgagag 480
 gagggctacg ttggtgagga ctgcggccag cggcagtgtc tgaatgcctg cagtgggcga 540

ggacaatgtg aggaggggct ctgcgtctgt gaagagggct accagggccc tgactgctca 600
gcagttgccc ctcca 615

<210> 15
<211> 555
<212> DNA
<213> Homo sapiens

<400> 15
atggaagacc tggaccagtc tcctctggtc tcgtcctcgg acagcccacc ccggccgcag 60
cccgcggttca agtaccagtt cgtgagggag ccgaggacg aggaggaaga agaggaggag 120
gaagaggagg acgaggacga agacctggag gagctggagg tgctggagag gaagcccgcc 180
gccgggctgt ccgcggcccc agtgcccacc gcccctgccg ccggcgcgcc cctgatggac 240
ttcggaatg acttcgtgcc gccggcgccc cggggacccc tgccggccgc tccccccgtc 300
gccccggagc ggcagccgtc ttgggacccg agcccgggtgt cgtcgaccgt gcccgcgcca 360
tccccgctgt ctgctgccgc agtctcgccc tccaagctcc ctgaggacga cgagcctccg 420
gcccggcctc cccctcctcc ccgggccagc gtgagccccc aggcagagcc cgtgtggacc 480
ccgccagccc cggctcccgc cgcgcccccc tccaccccgg ccgcgccc aa gcgcaggggc 540
tcctcgggct cagtg 555

<210> 16
<211> 198
<212> DNA
<213> Homo sapiens

<400> 16
aggatataca aggggtgtgat ccaagctatc cagaaatcag atgaaggcca cccattcagg 60
gcatatctgg aatctgaagt tgctatatct gaggagttgg ttcagaagta cagtaattct 120
gctcttggtc atgtgaactg cacgataaag gaactcaggc gcctcttctt agttgatgat 180
ttagttgatt ctctgaag 198

<210> 17
<211> 28
<212> DNA
<213> Artificial sequence

<220>
<223> PCR primer MAG1

<400> 17
cgggatccat gatattcctt accaccct 28

<210> 18
<211> 28

<212> DNA
 <213> Artificial sequence

<220>
 <223> PCR primer MAG2

<400> 18
 tccccgcggc tcggtgtgct ccctggaa 28

<210> 19
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PCR primer TNR1

<400> 19
 tccccgcggc atgtccatgt gccagttca 29

<210> 20
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PCR primer TNR2

<400> 20
 ttgcggccgc tggaggggca actgctga 28

<210> 21
 <211> 32
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PCR primer NogoN1

<400> 21
 ttgcggccgc aatggaagac ctggaccagt ct 32

<210> 22
 <211> 31
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PCR primer NogoN2

<400> 22
 aaactgcagc cactgagccc gaggagcccc t 31

<210> 23
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>

<223> PCR primer Nogo66-1

<400> 23

aaactgcagc aaggatatac aagggtgt

28

<210> 24

<211> 28

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer Nogo66-2

<400> 24

gctctagatc acttcagaga atcaacta

28

<210> 25

<211> 2934

<212> DNA

<213> Artificial sequence

<220>

<223> Construct resulting from sequentially connected PCR products

<400> 25

ggatccatga tattccttac caccctgcct ctgtttttgga taatgatttc agcttctcga	60
ggggggcact ggggtgcctg gatgccctcg tccatctcag ccttcgaggg cacgtgtgtc	120
tccatccccct gccgttttcga cttcccggat gagctcagac cggctgtggt acatggcgtc	180
tggtattttca acagtcacctt cccaagaac taccgcccag tggctcttcaa gtcccgcaca	240
caagtgggtcc acgagagctt ccagggccgt agccgcctgt tgggagacct gggcctacga	300
aactgcaccc tgcttctcag cacgctgagc cctgagctgg gagggaaata ctatttccga	360
ggtgacctgg gcggctacaa ccagtacacc ttctcggagc acagcgctcct ggacatcatc	420
aacacccccca acatcgtgggt gccccagaa gtggtggcag gaacggaagt agaggtcagc	480
tgcatgggtgc cggacaactg ccagagagctg cgccctgagc tgagctggct gggccacgag	540
gggctagggg agcccactgt tctgggtcgg ctgcgggagg atgaaggcac ctgggtgcag	600
gtgtcactgc tacacttcgt gcctactaga gaggccaacg gccaccgtct gggctgtcag	660
gctgccttcc ccaacaccac cttgcagttc gagggttacg ccagtctgga cgtcaagtac	720
cccccggtga ttgtggagat gaattcctct gtggaggcca ttgagggctc ccacgtcagc	780
ctgctctgtg gggctgacag caaccgcca ccgctgctga cttggatgcg ggatgggatg	840
gtgttgaggg aggcagttgc tgagagcctg tacctggatc tggaggaggt gaccccagca	900
gaggacggca tctatgcttg cctggcagag aatgcctatg gccaggacaa ccgcacggtg	960
gagctgagcg tcatgtatgc accttggaag cccacagtga atgggacggt ggtggcggtg	1020

gagggggaga cagtctccat cctgtgttcc acacagagca acccggaccc tattctcacc 1080
 atcttcaagg agaagcagat cctggccacg gtcattctatg agagtcagct gcagctggaa 1140
 ctccctgcag tgacgcccga ggacgatggg gagtactggg gtgtagctga gaaccagtat 1200
 ggccagagag ccaccgcctt caacctgtct gtggagtttg ctcccataat ctttctggaa 1260
 tcgcactgtg cagcggccag agacaccgtg cagtgcctgt gtgtggtaaa atccaaccg 1320
 gaaccctccg tggcctttga gctgccttcc cgcaacgtga ctgtgaacga gacagagagg 1380
 gagtttgtgt actcagagcg cagcggcctc ctgctcacca gcctcctcac gctccggggg 1440
 caggcccaag ccccaccccg cgtcatttgt acctccagga acctctacgg caccagagc 1500
 ctcgagctgc ctttccaggg agcacaccga gccgcggcat gtccatgtgc cagttcagcc 1560
 caggtgctgc aggagctgct gagccggatc gagatgctgg agagggagggt gtcggtgctg 1620
 cgagaccagt gcaacgccaa ctgctgccaa gaaagtgtg ccacaggaca actggactat 1680
 atccctcact gcagtggcca cggcaacttt agctttgagt cctgtggctg catctgcaac 1740
 gaaggctggg ttggcaagaa ttgctcggag ccctactgcc cgctgggttg ctccagccgg 1800
 ggggtgtgtg tggatggcca gtgcatctgt gacagcgaat acagcgggga tgactgttcc 1860
 gaactccggt gcccaacaga ctgcagctcc cgggggctct gcgtggacgg ggagtgtgtc 1920
 tgtgaagagc cctacactgg cgaggactgc agggaaactga ggtgccctgg ggactgttcg 1980
 ggggaagggga gatgtgccaa cggtaacctgt ttatgcgagg agggctacgt tggtagagg 2040
 tgccggccagc ggcagtgtct gaatgcctgc agtgggagc gacaatgtga ggaggggctc 2100
 tgctgtctgt aagagggcta ccagggccct gactgctcag cagttgcccc tccagcggcc 2160
 gcaatggaag acctggacca gtctcctctg gtctcgtcct cggacagccc acccggccg 2220
 cagcccgcgt tcaagtacca gttcgtgagg gagcccgagg acgaggagga agaagaggag 2280
 gaggaagagg aggacgagga cgaagacctg gaggagctgg aggtgctgga gaggaagccc 2340
 gccgccgggc tgtccgcggc ccagtgccc accgcccctg ccgccggcgc gccctgatg 2400
 gacttcggaa atgacttcgt gccgcggcg cccgggggac ccctgccggc cgctcccccc 2460
 gtcgccccgg agcggcagcc gtcttgggac ccgagcccg tgctcgtcag cgtgcccgcg 2520
 ccatccccgc tgtctgctgc cgcagtctcg ccctccaagc tccctgagga cgacgagcct 2580
 ccggcccggc ctccccctcc tccccgggc agcgtgagcc ccaggcaga gcccggtgtg 2640
 acccggccag ccccggtctc cgccgcgccc ccctccaccc cggccgcgccc caagcgcagg 2700
 ggctcctcgg gctcagtggc tgcagcaagg atatacaagg gtgtgatcca agctatccag 2760
 aatcagatg aaggccaccc attcagggca tatctggaat ctgaagttgc tatatctgag 2820
 gagttggttc agaagtacag taattctgct cttgggtcatg tgaactgcac gataaaggaa 2880

ctcaggcgcc tcttcttagt tgatgattta gttgattctc tgaagtgatc taga 2934

<210> 26
 <211> 42
 <212> DNA
 <213> M13 coliphage

<400> 26
 ttattcgcaa ttcctttagt ggtacctttc tattctcact ct 42

<210> 27
 <211> 33
 <212> DNA
 <213> M13 coliphage

<400> 27
 ggtggagggt cggccgaaac tgttgaaagt tgt 33

<210> 28
 <211> 21
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary 7-mer peptide-encoding sequence

<400> 28
 tatctgacgc agcctcagtc g 21

<210> 29
 <211> 21
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary 7-mer peptide-encoding sequence

<400> 29
 ggttctctgc ctcatcgcct g 21

<210> 30
 <211> 21
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary 7-mer peptide-encoding sequence

<400> 30
 acgcagctgt ttcctcctta g 21

<210> 31
 <211> 21
 <212> DNA
 <213> Artificial sequence

<220>
<223> Exemplary 7-mer peptide-encoding sequence

<400> 31
cattctattc ctgataatat t 21

<210> 32
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary 7-mer peptide-encoding sequence

<400> 32
catcatatgc ctcatgataa g 21

<210> 33
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary 7-mer peptide-encoding sequence

<400> 33
tatacgacgc ctccgagtcc t 21

<210> 34
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary 7-mer peptide-encoding sequence

<400> 34
cagcttccgc ttatgcctcg t 21

<210> 35
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary 7-mer peptide-encoding sequence

<400> 35
acgcagctgt ttcctcctca g 21

Claims

1. A peptide, the amino acid sequence of which consists of an amino acid sequence selected from the group consisting of:

YLTQPQS (SEQ ID NO. 1);
GSLPHSL (SEQ ID NO. 2);
TQLFPPQ (SEQ ID NO. 3);
HSIPDNI (SEQ ID NO. 4);
HHMPHDK (SEQ ID NO. 5);
YTTPPSP (SEQ ID NO. 6); and
QLPLMPR (SEQ ID NO. 7).

2. The peptide of claim 1, wherein the amino acid sequence is selected from the group consisting of:

YLTQPQS (SEQ ID NO. 1); and
TQLFPPQ (SEQ ID NO. 3).

3. A peptide up to 60 amino acids in length comprising an amino acid sequence selected from the group consisting of:

YLTQPQS (SEQ ID NO. 1);
GSLPHSL (SEQ ID NO. 2);
TQLFPPQ (SEQ ID NO. 3);
HSIPDNI (SEQ ID NO. 4);
HHMPHDK (SEQ ID NO. 5);
YTTPPSP (SEQ ID NO. 6); and
QLPLMPR (SEQ ID NO. 7),

wherein the peptide is capable of binding to Nogo, MAG and/or TN-R.

4. The peptide of claim 3, which comprises the amino acid sequence YLTQPQS (SEQ ID NO. 1) or TQLFPPQ (SEQ ID NO. 3).

5. A peptide up to 60 amino acids in length comprising an amino acid sequence having at least 5 residues identical with

corresponding residues in an amino acid sequence selected from the group consisting of:

YLTQPQS (SEQ ID NO. 1);
GSLPHSL (SEQ ID NO. 2);
TQLFPPQ (SEQ ID NO. 3);
HSIPDNI (SEQ ID NO. 4);
HHMPHDK (SEQ ID NO. 5);
YTTPPSP (SEQ ID NO. 6); and
QLPLMPR (SEQ ID NO. 7),

wherein the peptide is capable of binding to Nogo, MAG and/or TN-R.

6. The peptide of claim 5, which has at least 5 residues identical with corresponding residues in an amino acid sequence selected from the group consisting of:

YLTQPQS (SEQ ID NO. 1); and
TQLFPPQ (SEQ ID NO. 3).

7. The peptide of claim 5 or claim 6, wherein the number of identical residues is at least 6.

8. The peptide of any one of claims 3 to 7, which is capable of binding to Nogo-66 and/or TNR-EGFL.

9. The peptide of any one of claims 3 to 8, which is up to 40 amino acids in length.

10. The peptide of claim 9, which is up to 20 amino acids in length.

11. The peptide of claim 10, which is up to 10 amino acids in length.

12. A composition comprising one or more peptides according to any preceding claim, together with one or more pharmaceutically acceptable ingredients.

13. A peptide according to any one of claims 1 to 11 for use in a method of treatment.

14. The use of a peptide according to any one of claims 1 to 11 in the preparation of a medicament for the treatment of CNS damage.

15. A method for treating CNS damage, the method comprising administering a peptide according to any one of claims 1 to 11 to a patient at or near a site of CNS damage in the patient.

16. A method for treating spinal cord injury or stroke, the method comprising administering to a patient a peptide having an amino acid sequence that consists of an amino acid sequence selected from the group consisting of:

YLTQPQS (SEQ ID NO. 1); and

TQLFPPQ (SEQ ID NO. 3),

by direct injection into a site of spinal cord injury or stroke damage in the patient.

17. The use of a peptide according to any one of claims 1 to 11 and/or a computer-generated model thereof, in the design of a mimetic capable of binding to one or more of the neuronal growth inhibitory molecules Nogo, MAG and/or TN-R.

18. A method of designing a mimetic of a peptide as defined in any one of claims 1 to 11, the mimetic being capable of binding to one or more of the neuronal growth inhibitory molecules Nogo, MAG and/or TN-R, said method comprising:

(i) analysing a peptide as defined in any one of claims 1 to 11 that is capable of binding to one or more of the neuronal growth inhibitory molecules Nogo, MAG and/or TN-R to determine the amino acid residues essential and important for the activity to define a pharmacophore; and

(ii) modelling the pharmacophore to design and/or screen candidate mimetics having the biological activity.

19. The use or method of claim 17 or claim 18, which includes a step of assaying binding of a candidate mimetic to Nogo, MAG and/or TN-R in vitro.

20. The use or method of any one of claims 17 to 19, which includes a step, having identified a candidate mimetic that is capable of such in vitro binding, of optimizing the candidate mimetic for in vivo use.

21. The use or method of claim 20, wherein the optimised mimetic is formulated together with one or more pharmaceutically acceptable ingredients.

22. A bacteriophage which expresses a fusion protein consisting of a peptide and a bacteriophage coat protein, such that the peptide is displayed on the surface of the bacteriophage virion, wherein the peptide is as defined in any one of claims 1 to 11.

23. A screening method for peptides capable of binding to Nogo, MAG and/or TN-R, the method comprising:

providing bacteriophages of claim 22, respectively expressing different peptides; and

screening the bacteriophages for the ability to bind to Nogo, MAG and/or TN-R.

24. The method of claim 23, wherein bacteriophages which are identified as being capable of binding to Nogo, MAG and/or TN-R, or the peptides they display, are then be screened for the ability to block the inhibitory effects of Nogo, MAG and/or TN-R on neuronal cell adhesion in an in vitro assay.

25. A method comprising all the steps of claim 24 and an additional step, following the identification of a peptide, or phage that displays a peptide, that is capable of blocking the inhibitory effects of Nogo, MAG and/or TN-R on neuronal cell adhesion in an in vitro assay, of formulating the peptide with one or more pharmaceutically acceptable ingredients for administration in vivo.

26. A method of searching for factors that are likely to reduce the inhibitory effect of TN-R, MAG and/or Nogo, the method comprising interrogating a sequence database to identify polypeptides, or nucleic acids that encode polypeptides, that comprise an amino acid sequence having at least 5 residues identical with corresponding residues in an amino acid sequence selected from the group consisting of:

YLTQPQS (SEQ ID NO. 1);
GSLPHSL (SEQ ID NO. 2);
TQLFPPQ (SEQ ID NO. 3);
HSIPDNI (SEQ ID NO. 4);
HHMPHDK (SEQ ID NO. 5);
YTTPPSP (SEQ ID NO. 6); and
QLPLMPR (SEQ ID NO. 7).

27. A method of searching for factors that are likely to reduce the inhibitory effect of TN-R, MAG and/or Nogo, the method comprising screening a cDNA library with an oligonucleotide probe which is capable of hybridising under stringent conditions with a nucleic acid sequence that encodes

an amino acid sequence having at least 5 residues identical with corresponding residues in an amino acid sequence selected from the group consisting of:

YLTQPQS (SEQ ID NO. 1);
GSLPHSL (SEQ ID NO. 2);
TQLFPPQ (SEQ ID NO. 3);
HSIPDNI (SEQ ID NO. 4);
HHMPHDK (SEQ ID NO. 5);
YTTPPSP (SEQ ID NO. 6); and
QLPLMPR (SEQ ID NO. 7).

28. The method of claim 26 or claim 27, which includes the step, following the identification of a candidate polypeptide or nucleic acid encoding the candidate polypeptide, of testing the polypeptide for the ability to reduce the inhibitory effect of TN-R, MAG and/or Nogo.

29. A method comprising all the steps of claim 28 and an additional step, following the identification of a polypeptide that is capable of blocking the inhibitory effects of Nogo, MAG and/or TN-R on neuronal cell adhesion in an in vitro assay, of formulating the polypeptide with one or more pharmaceutically acceptable ingredients for administration in vivo.

30. A nucleic acid vector comprising nucleic acid encoding one or more polypeptide domains selected from the group consisting of:

(a) the N-terminal domain (NogoN) of Nogo-A, or a variant or fragment thereof;

(b) the extracellular loop (Nogo66) of Nogo-B, or a variant or fragment thereof;

(c) the third to fifth immunoglobulin-like repeats of MAG, or a variant or fragment thereof; and

(d) the EGF-like domain of TN-R, or a variant or fragment thereof,

wherein said fragment comprises at least 15 contiguous amino acids from said domain, includes one or more epitopes of said domain and retains the ability to raise an antibody response in vivo, and

wherein said variant includes a portion of at least 15 amino acids that has at least 65% amino acid identity to a corresponding portion of said domain.

31. The vector of claim 30, wherein the nucleic acid encodes at least two of the domains.

32. The vector of claim 31, wherein the domains are expressed as a fusion polypeptide.

33. The vector of claim 32, wherein the domains are separated from one another by flexible linkers.

34. The vector of any one of claims 30 to 33 wherein, of the proteins Nogo A, Nogo B, TN-R and/or MAG, the vector is preferably capable of expressing substantially only the domains (a), (b), (c) and/or (d) recited in claim 30.

35. The vector of claim 34, wherein the vector is incapable of expressing other epitope-containing portions of the proteins.

36. The vector of claim 34 or claim 35, wherein, of the proteins Nogo A, Nogo B, TN-R and/or MAG, the vector preferably expresses no more than 20% of the protein lying outside domains (a) to (d) recited in claim 30.

37. The vector of any one of claims 30 to 36, wherein the domain (a) has the amino acid sequence of NogoN (1-185) (SEQ ID NO:10), domain (b) has the amino acid sequence of Nogo66 (823-888) (SEQ ID NO:11), domain (c) has the amino acid sequence of MAG (1-508) (SEQ ID NO:8), and domain (d) has the amino acid sequence of TNR (125-329) (SEQ ID NO:9).

38. The vector of claim 30, which encodes a polypeptide having the amino acid sequence MAG(1-508)-Ala_n-TNR(125-329)-Ala_n-NogoN(1-185)-Ala_n-Nogo66(823-888) (SEQ ID NO:12), where Ala_n represents an polyalanine linker.

39. A composition comprising the vector of any one of claims 30 to 38, formulated together with one or more pharmaceutically acceptable ingredients for use as a therapeutic vaccine.

40. The vector of any one of claims 30 to 38, for use in a method of treatment.

41. Use of the vector of any one of claims 30 to 38 in the manufacture of a medicament for the treatment of CNS damage.

42. A method for treating CNS damage in a patient, the method comprising administering the vector of any one of claims 30 to 38 to the patient as a therapeutic vaccine.

43. A polypeptide consisting essentially of one or more polypeptide domains as defined in claim 30.

44. The polypeptide of claim 43, which is encoded by the vector of any one of claims 30-38.

45. A composition comprising the polypeptide of claim 43 or claim 44, formulated together with one or more pharmaceutically acceptable ingredients for use as a therapeutic vaccine.

46. The polypeptide of claim 43 or claim 44, for use in a method of treatment.

47. Use of the polypeptide of claim 43 or claim 44 in the manufacture of a medicament for the treatment of CNS damage.

48. A method for treating CNS damage in a patient, the method comprising administering the polypeptide of claim 43 or claim 44 to the patient as a therapeutic vaccine.

49. An antibody capable of specifically binding to any one of domains (a)-(d) as defined in claim 37, or a mixture of antibodies together capable of binding to two, three or all four of domains (a)-(d) as defined in claim 37, for use in a method of treatment.

50. Use of an antibody capable of specifically binding to any one of domains (a)-(d) as defined in claim 37, or a mixture of antibodies together capable of binding to two, three or all four of domains (a)-(d) as defined in claim 37, in the manufacture of a medicament for the treatment of CNS damage.

51. A method for treating CNS damage in a patient, the method comprising administering to the patient as a therapeutic vaccine an antibody capable of specifically binding to any one of domains (a)-(d) as defined in claim 37, or a mixture of antibodies together capable of binding to two, three or all four of domains (a)-(d) as defined in claim 37.

52. A composition comprising an antibody capable of specifically binding to any one of domains (a)-(d) as defined in claim 37, or a mixture of antibodies together capable of binding to two, three or all four of domains (a)-(d) as defined in claim 37, formulated together with one or more pharmaceutically acceptable ingredients for use as a therapeutic vaccine.

53. The composition of any one of claims 12, 39, 45 and 52, which is formulated for administration by injection.

54. The peptide of claim 13, the vector of claim 40, the polypeptide of claim 46 or the antibody of claim 49, wherein the treatment is the treatment of CNS damage.

55. The peptide of claim 13, the vector of claim 40, the polypeptide of claim 46 or the antibody of claim 49, wherein the treatment is the treatment of spinal cord injury or stroke.

56. The use of any one of claims 14, 41, 47 and 50, wherein the treatment is of spinal cord injury or stroke.

Fig. 1

PCR primers

MAG1: 5- CG GGA TCC ATG ATA TTC CTT ACC ACC CT
 BamH I Met

MAG2: 5- TCC C CGC GGC TCG GTG TGC TCC CTG GAA
 Sac II

TNR1: 5- TCC CC GCG GCA TGT CCA TGT GCC AGT TCA
 Sac II

TNR2: 5- TT GC GGC CGC TGG AGG GGC AAC TGC TGA
 Not I

NogoN1: 5- TT GCG GCC GCA ATG GAA GAC CTG GAC CAG TCT
 Not I

NogoN2: 5- AAA C TGC AGC CAC TGA GCC CGA GGA GCC CCT
 Pst I

Nogo66-1: 5- AAA CT GCA GCA AGG ATA TAC AAG GGT GT
 Pst I

Nogo66-2: 5- GC TCT AGA TCA CTT CAG AGA ATC AAC TA
 Xba I ***

Construct resulting from sequentially connected PCR products

5' - GGA TCC (MAG) GCC GCG GCA (TNR) GCG GCC GCA (NogoN) GCT GCA GCA
 BamH I Sac II Not I Pst I

(Nogo66) TGA TCT AGA -3'
 Xba I